The Digital International Liver Congress™ 2020


27-29 August 2020
N. Poster
Poster title
Applicant name
  SAT-001 Lipoprotein lipase deletion induces a proinflammatory phenoytpe in liver-infiltrating monocytes during non-alcoholic steatohepatits Anja Koop Received Received
  FRI-001 The development of the naf3 score to accurately predict the presence of active NASH with advanced fibrosis Naim Alkhouri Received Received
  LBP-001 Multifactorial effects of AXA1125 and AXA1957 observed on markers of metabolism, inflammation and fibrosis: a 16-week randomized placebo-controlled study in subjects with non-alcoholic fatty liver disease (NAFLD) with and without type 2 diabetes (T2D) Carrie Bray Received Received
  SAT-002 A translational mouse model for NASH and advanced fibrosis in association with atherosclerosis Anita van den Hoek Received Received
  SAT-003 Aberrant hepatic protein tyrosine phosphatase receptor type delta expression is a driver of metabolic liver disease Armando Andres Roca Suarez Received Received
  THU-003 Non-alcoholic fatty liver disease fibrosis score predicts cardiovascular mortality in post percutaneous coronary intervention patients: 5-year results from an observational registry Dongyoung Lee Received Received
  FRI-003 Machine learning models identify novel histologic features predictive of clinical disease progression in patients with advanced fibrosis due to non-alcoholic steatohepatitis Vicki Mountain Received Received
  SAT-004 LncRNA-H19 as a marker of liver progression from steatosis to hepatocellular carcinoma Ángela Rojas Received Received
  LBP-005 Antiviral activity, pharmacokinetics and safety of the second-generation hepatitis B core inhibitor ABI-H2158 in Phase 1b study of patients with HBeAg-positive chronic hepatitis B infection Lisa Danzig Received Received
  FRI-005 Performance of non-invasive fibrosis tests among non-alcoholic fatty liver disease (NAFLD) patients with normal alanine aminotransferase (alt): data from a large North American primary care NAFLD pathway Abdel Aziz Shaheen Received Received
  FRI-006 Non-invasive detection of NASH and significant fibrosis in NAFLD patients with low FIB-4 Heike Bantel Received Received
  SAT-006 AXL inhibition prevents NAFLD progression in mice with soluble AXL as marker of the NAFLD to NASH transition Anna Tutusaus Received Received
  SAT-007 Efficacy and safety of an acetyl CoA carboxylase inhibitor are improved in combination with PPAR agonists in a dyslipidemic rat model ARCHANA VIJAYAKUMAR Received Received
  LBP-008 faecal microbiota transplantation reduces pathogenic burden and is anti-inflammatory in patients with advanced cirrhosis Lindsey Ann Edwards Received Received
  FRI-008 Predictive modelling to identify and characterize fast progressors among patients with non-alcoholic steatohepatitis (NASH) Brenda Reinhart Received Received
  FRI-009 Non-invasive tests for assessing fibrosis in patients with non-alcoholic fatty liver disease: an evaluation of combining test results Sari Rizk Received Received
  LBP-009 The impact on mortality of a national hepatitis C elimination program, Georgia, 2015-2019 Lia Gvinjilia Received Received
  SAT-010 Intermittent hypoxia featuring the obstructive sleep apnea syndrome contributes to hepatosteatosis by upregulating the intrahepatic expression of fatty acid translocase CD36 and lipogenic genes Carmelo Garcia-Monzon Received Received
  LBP-010 Bariatric surgery is not associated with a reduction in risk of severe liver disease in comparison to standard obesity treatment in 3,922 subjects Hannes Hagstrm Received Received
  THU-010 PNPLA3 gene polymorphism and overall and cardiovascular mortality among non-alcoholic fatty liver disease in the United States Karn Wijarnpreecha Received Received
  FRI-011 Interplay between metabolic derangement, biomarkers of collagen remodeling and macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease Chiara Rosso Received Received
  SAT-011 The symbiotic supplementation modulate gut microbiota, regulation beta-catenin expression and prevents weight gain in ob/ob mice with non-alcoholic fatty liver disease (NAFLD) Claudia Oliveira Received Received
  LBP-012 Efficacy and safety results of the phase 2 JNJ-56136379 JADE study in patients with chronic hepatitis B: Interim week 24 data Harry Janssen Received Received
  SAT-012 Treatment with the endothelin receptor inhibitor bosentan alleviates the NAFLD-associated increased intrahepatic vascular resistance and reduces steatosis and liver damage in a rat model of early NAFLD Denise van der Graaff Received Received
  FRI-013 Mack-3: an accurate blood test for the diagnosis of fibrotic NASH and a candidate biomarker to monitor disease progression Clémence Canivet Received Received
  LBP-013 A Phase 2 Study of Peginterferon Lambda, Lonafarnib and Ritonavir for 24 Weeks: End-of-Treatment Results from the LIFT HDV Study Christopher Koh Received Received
  LBP-014 Proof-of-concept use of machine learning to predict tumor recurrence of early-stage hepatocellular carcinoma before therapy using baseline magnetic resonance imaging Ahmet Said Kckkaya Received Received
  SAT-014 Identification of novel biomarkers and therapeutic targets for steatohepatitis and advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD): an in silico analysis Douglas Maya-Miles Received Received
  FRI-014 Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD score) on NAFLD in a mixed Latin American population Claudia Oliveira Received Received
  FRI-015 Identification of significant fibrosis in patients with non-alcoholic steatohepatitis using non-invasive tests: determination of optimal thresholds based on cross-sectional analyses of patients screened for a phase 3 randomised controlled trial Darshini Shah Received Received
  LBP-015 Hepatocyte-specific deficiency of sphingosine kinase 1 exacerbates acetaminophen-induced liver injury Tian Lan Received Received
  FRI-016 Patients with non-alcoholic fatty liver disease referred from primary care have a significant serum fibrosis marker and liver stiffness measurement discordance David Harman Received Received
  SAT-017 Propionate intervention attenuates NASH while negatively affecting cognition Eveline Gart Received Received
  THU-017 Association between non-alcoholic fatty liver disease and nut consumption Georg Semmler Received Received
  LBP-018 JKB-122 in subjects with non-alcoholic fatty liver disease (NAFLD): a phase 2, randomized, multiple-dose, double-blind, placebo-controlled study Sheng-Hung Liu Received Received
  THU-018 Myosteatosis and sarcopenia are prevalent in patients with NAFLD even in the absence of advanced fibrosis Giada Pallini Received Received
  SAT-018 A shortcut from non-alcoholic fatty liver disease to HCC: c-Myc, a promising theranostic target Feifei Guo Received Received
  FRI-018 Digital image analysis for quantitative evaluation of fibrosis, steatosis, inflammation and iron overload in patients with non-alcoholic fatty liver disease David Marti-Aguado Received Received
  THU-019 A cholestatic pattern predicts liver outcomes in patients with non-alcoholic fatty liver disease Grazia Pennisi Received Received
  SAT-020 Hepatocyte-specific deletion of ERK5 worsens insulin resistance in a murine model of non-alcoholic fatty liver disease (NAFLD) Giovanni Di Maira Received Received
  SAT-021 MicroRNAs involved in the progression of non-alcoholic fatty liver Guillermo Nahúm López-Sánchez Received Received
  THU-021 Serum zinc level and liver fibrosis in male patients with non-alcoholic fatty liver disease Won Sohn Received Received
  FRI-021 Diagnostic accuracy of acoustic radiation force impulse elastography for the staging of hepatic fibrosis in non-alcoholic fatty liver disease: a systematic review and meta-analysis Emmanuel Selvaraj Received Received
  LBP-022 Screening for non-alcoholic fatty liver disease in persons with type 2 diabetes in the U.S. is cost effective: A comprehensive economical analysis Eric Mitchell Received Received
  FRI-022 Three is enough: optimization of regions of interest ion for accurate estimation of proton density fat fraction in liver from magnetic resonance images Florent Roche Received Received
  THU-022 Identification of factors associated with engagement and adherence to a very low calorie diet to achieve significant weight loss in patients with advanced non-alcoholic fatty liver disease: a qualitative evaluation Jadine Scragg Received Received
  FRI-023 Diagnostic accuracy of magnetic resonance elastography for the staging of fibrosis and diagnosis of steatohepatitis in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis Ferenc Mozes Received Received
  LBP-023 CHESS criteria for the screening of varices in patients with compensated advanced chronic liver disease: a multicenter study Xiaolong Qi Received Received
  SAT-025 The influence of TRPM8 variant on brown adipose tissue activity and contribution to increased susceptibility to non-alcoholic fatty liver disease among South Asians JANE GROVE Received Received
  THU-025 Fibrosis quantification by image morphometry of liver fibrosis predicts clinical outcomes in patients with non-alcoholic fatty liver disease Zhengyi Wang Received Received
  FRI-026 The prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus Leen Heyens Received Received
  FRI-027 Validation of interleukin-32 as a new circulating fatty liver biomarker Guido Alessandro Baselli Received Received
  SAT-028 High-throughput sequencing identified MIR-193a as a potential biomarker of non-alcoholic fatty liver disease activity Katherine Johnson Received Received
  THU-028 The association with low skeletal muscle mass and carotid atherosclerosis in patients with non-alcoholic fatty liver disease Min Kyu Kang Received Received
  THU-029 Gender difference and hepatocellular carcinoma incidence in non-alcoholic steatohepatitis patients with advanced liver fibrosis Kanokwan Pinyopornpanish Received Received
  SAT-029 Ageing causes lipid metabolism imbalance and exacerbates steatohepatitis in high-fat diet-fed mice Kazuyoshi Kon Received Received
  FRI-029 Adherence to established process measures in the evaluation of hepatic steatosis on imaging in a large tertiary care network Hersh Shroff Received Received
  LBP-030 Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-positive chronic hepatitis B infection in a long-term extension study Lisa Danzig Received Received
  FRI-031 Utilizing pre-existing imaging and data lake technology in the search of clinically neglected non-alcoholic fatty liver disease (NAFLD) Iiro Karhiaho Received Received
  LBP-031 Machine learning identifies histologic features associated with regression of cirrhosis in treatment for chronic hepatitis B Oscar Zevallos Received Received
  THU-031 Histological renal damage and eligibility for kidney donation are worse in patients with biopsy-proven non-alcoholic steatohepatitis compared with simple steatosis Lorenzo Mulazzani Received Received
  LBP-032 Long-term survival of repeat hepatic resection and radiofrequency ablation for patients with recurrent hepatocellular carcinoma: a multicentric study Jian-Hong Zhong Received Received
  SAT-032 Anti-inflammatory and anti-fibrotic activity of TERN-201, a semicarbazide-sensitive amine oxidase inhibitor, in a rat choline-deficient high-fat diet non-alcoholic steatohepatitis model Martijn Fenaux Received Received
  LBP-033 Analysis of HBsAg levels, HBsAg isoforms, HBsAg immune complexes, HBV pregenomic RNA and HBcrAg dynamics during and after NAP-based combination therapy in the REP 301-LTF and REP 401 studies Andrew Vaillant Received Received
  THU-033 Incidence and risk factors for cardiovascular events in patients with advanced fibrosis due to non-alcoholic steatohepatitis: data from the phase 3 STELLAR trials Marianne Camargo Received Received
  FRI-034 Accuracy of cytokeratin-18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: a systematic review and meta-analysis Jenny Lee Received Received
  SAT-034 Thr -ive agonist MGL-3196 improves NAS score and plasma lipoprotein profile in the liver-humanized FRGN KO NASH model LANDER FOQUET Received Received
  THU-034 A substantial number of patients with non-alcoholic fatty liver disease and type 2 diabetes have advanced liver fibrosis with a normal serum alanine transaminase Michael Patrick Johnston Received Received
  THU-035 Unlike HbA1c level and the amount of visceral adipose tissue, the presence and severity of NAFLD do not predict the occurrence of major adverse cardiovascular events in an obese Belgian population Mikhail Van Herck Received Received
  SAT-035 TM6SF2/PNPLA3/MBOAT7 loss-of function genetic variants impact on NAFLD development and progression both in patients and in in vitro models Miriam Longo Received Received
  SAT-036 Enhancing autophagy improves and slows the progression of non-alcoholic steatohepatitis disease Maria Ruart Millán Received Received
  THU-036 Association of FIB-4 score with disease progression in real-world populations diagnosed with NAFLD/NASH or at risk of NASH in US clinical practice Michelle Lai Received Received
  THU-037 Association of FIB-4 score with major cardiovascular events (MACE) in real-world populations diagnosed with NASH or NAFLD in US clinical practice Michelle Lai Received Received
  SAT-037 The PSRC1 rs599839 AG variant disentangles the risk of coronary artery disease and hepatocellular carcinoma in Italian NAFLD patients Marica Meroni Received Received
  FRI-038 Phenome-wide association study of the FIB-4 index in a large, populational-based study in the United States Andrew Billin Received Received
  SAT-038 The FASN inhibitor TVB-2640 is efficacious in a new 3D human liver microtissue model of NASH Marie OFarrell Received Received
  THU-038 Relevance of social support and severity of liver disease in biopsychosocial profiles of patients with non-alcoholic fatty liver disease Jesús Funuyet-Salas Received Received
  FRI-040 Macrophage markers do not add to the prediction of liver fibrosis by transient elastography in patients with non-alcoholic fatty liver disease Konstantin Kazankov Received Received
  SAT-041 Hepatic RIPK3 signalling differentially modulates lipid metabolism and inflammation in non-alcoholic fatty liver disease Marta B. Afonso Received Received
  THU-041 Muscle fat infiltration in obese patients is associated with NAFLD related fibrosis severity - results from a prospective imaging study Nicolas Lanthier Received Received
  FRI-042 ELF test should be used concurrently with elastography in NAFLD to maximize diagnostic accuracy Laura Iogna Prat Received Received
  THU-042 Exercise performance in patients with non-alcoholic steatohepatitis Oliver Glass Received Received
  SAT-044 Efficacy and safety of combination therapy with elobixibat and colestyramine for non-alcoholic steatohepatitis model mice Michihiro Iwaki Received Received
  FRI-044 Serum exosomal miRNA-4668-5p as potential biomarker for advanced fibrosis in non-alcoholic fatty liver disease Young-Sun Lee Received Received
  THU-044 Obesity and alcohol intake modify the impact of genetic variants on the risk for incident liver disease in the general population Panu Luukkonen Received Received
  FRI-046 Patient-reported symptoms and impact in non-alcoholic steatohepatitis: an evaluation of the NASH-check, a novel prom in NASH Ramakrishna GS Received Received
  THU-046 Barriers and motivators to engaging in physical activity in individuals with NAFLD: implications for physical activity adherence Philip OGorman Received Received
  SAT-046 Muscle fat is higher in NAFLD, and increases with fibrosis stage - a retrospective liver biopsy controlled magnetic resonance imaging-based body composition study Mikael Forsgren Received Received
  SAT-047 Adoptive cell transfer of regulatory T cells causes an exacerbation of hepatic steatosis in high-fat high-fructose diet-fed mice Mikhail Van Herck Received Received
  FRI-047 The FGF19 analogue aldafermin improves non-invasive tests in patients with non-alcoholic steatohepatitis Marno Ryan Received Received
  THU-047 Serious complications due to study-mandated liver biopsies in phase 3 trials for patients with advanced fibrosis due to non-alcoholic steatohepatitis Kathryn Kersey Received Received
  THU-048 The burden of disease associated with non-alcoholic steatohepatitis patients under standard of care Sari Rizk Received Received
  FRI-048 Evaluating the patient-perceived impact of non-alcoholic steatohepatitis with compensated cirrhosis Ramakrishna GS Received Received
  SAT-048 Synergic effect of a combined treatment with atorvastatin and ambrisentan in a rat model of NASH Miren Bravo Received Received
  THU-050 NAFLD fibrosis score identifies not only advanced liver fibrosis but also chronic vascular complications in type 2 diabetic patients Rosa Lombardi Received Received
  FRI-050 Liver incytes: assessment of fibrosis and steatosis in patients and healthy volunteers Michael Curry Received Received
  SAT-051 Blocking IL-1 signaling in hepatocytes undergoing metabolic stress protects against metabolic inflammation and attenuates pro-coagulant factors Nadine Gehrke Received Received
  SAT-052 Monocyte chemoattractant protein-induced protein 1 level negatively correlates with steatosis in fatty liver patients Natalia Pydyn Received Received
  THU-052 Clinical and economic impact of non-alcoholic fatty liver disease in Spain María Sainz Received Received
  SAT-053 Ultrastructural changes in perfusion-fixed human non-alcoholic fatty liver disease biopsies Pauline Verhaegh Received Received
  FRI-053 Drivers of diagnosis and referral decisions in non-alcoholic fatty liver disease patients martina klinger sikora Received Received
  SAT-054 mIR-21 is increased in patients with NASH-associated HCC and contributes to hepatocarcinogenesis in mice with NAFLD Rodrigues Pedro Received Received
  FRI-055 Serum lipidomic landscape of non-alcoholic fatty liver disease progression to hepatocellular carcinoma in a Caucasian population Monika Lewinska Received Received
  THU-055 A national cross-sectional survey of health-related quality of life in Chinese patients with non-alcoholic fatty liver disease Rui Huang Received Received
  FRI-056 Difference between antinuclear antibody-positive non-alcoholic steatohepatitis and autoimmune hepatitis based on differential patterns of peripheral T lymphocytes Akira Kado Received Received
  SAT-056 Recombinant glutamine synthetase reduces ammonia and hepatic fibrosis in in vitro and in vivo models of non-alchoholic fatty liver disease Antria Siakalli Received Received
  THU-056 Risk factors associated with subclinical atherosclerosis in the patients with biopsy-proven non-alcoholic fatty liver disease Taeang Arai Received Received
  THU-057 Progression of non-alcoholic fatty liver disease is rare in a Danish tertiary liver centre Tea Lund Laursen Received Received
  FRI-057 Utility of metabolomic biomarkers to identify non-alcoholic fatty liver disease in liver transplant recipients Christopher Mowry Received Received
  FRI-058 Cost-effectivity analysis of several non-invasive test strategies for detection and referral of patients with non-alcoholic fatty liver disease at risk of advanced fibrosis Bianca Sánchez Received Received
  SAT-058 GPNMB modulates hepatic steatogenesis and liver cancer Seddik Seddik Hammad Received Received
  FRI-059 Prediction of advanced fibrosis with transient elastography is superior to gut microbiota-based approaches in non-alcoholic fatty liver disease Sonja Lang Received Received
  SAT-059 TM6SF2 E167K variant increases the severity of NAFLD in high fat diet-fed mice Shousheng Liu Received Received
  THU-060 First 1-year follow up data from the German NAFLD prospective real-life cohort (FLAG study) show low frequencies of lifestyle changes Wolf Peter Hofmann Received Received
  FRI-060 The accuracy of the fast score in predicting NASH with significant fibrosis Nabil Noureddin Received Received
  SAT-060 Unrevealing the HDL lipidome in NAFLD: a possible explanation for the increased CVD risk of these patients Sofia Kartsoli Received Received
  THU-061 Fibrosis non-invasive tests capture changes in patient-reported outcomes of patients with advanced non-alcoholic steatohepatitis Carey Escheik Received Received
  SAT-061 A novel small molecule modulating the mitochondrial NEET (CISD) proteins activity improves inflammation and fibrosis in a diet-induced model of non-alcoholic steatohepatitis Stéphanie Le Corre Received Received
  FRI-062 Expanding the use of the vibration controlled transient elastography in morbid obese patients: validation of a new automated adaptive measurement depths algorithm in a large pooled NAFLD cohort Anne LLORCA Received Received
  THU-062 Gut transcriptomics reveals potential therapeutic strategies for the restoration of epithelial barrier repair in alcohol-related liver cirrhosis Antonio Riva Received Received
  THU-063 Specific alterations of the immune checkpoint secretome are linked with antibacterial immunity in alcohol-related liver disease Antonio Riva Received Received
  THU-065 Analysis of the influence of alcoholic abstinence on mortality in patients with alcoholic liver cirrhosis Ángela Suárez-Noya Received Received
  SAT-065 Infiltrative monocyte derived adenosine deaminase 2 promotes liver fibrosis via signaling through extracellular inosine Shilpa Tiwari Heckler Received Received
  FRI-065 Liver derived apoptotic microparticles as biomarkers to detect transition from simple steatosis to steatohepatitis in non-alcoholic fatty liver disease Rocío Muñoz Received Received
  SAT-066 TERN-501, a potent and ive agonist of thyroid hormone receptor beta, strongly reduces histological features and biomarkers of non-alcoholic steatohepatitis associated pathology in rodent models Martijn Fenaux Received Received
  FRI-066 Obeticholic acid improves hepatic fibroinflammation as assessed by multiparametric magnetic resonance imaging: interim results of the regenerate trial Sari Rizk Received Received
  THU-066 Non-invasive criteria for diagnosis of alcoholic hepatitis: use in clinical practice and correlation with prognosis Emma Avitabile Received Received
  FRI-067 Liver stiffness measurement by fibroscan predicts the occurrence of liver-related events and death in patients with NAFLD-related compensated advanced chronic liver disease Salvatore Petta Received Received
  FRI-068 Glympse liver test for noninvasive monitoring of combination drug therapy in a rat model of non-alcoholic steatohepatitis (NASH) Sophie Cazanave Received Received
  THU-068 Alcohol recurrence and outcome in patients transplanted for alcoholic cirrhosis: impact of the 6-month rule Claire Perignon Received Received
  SAT-069 Chorionic-plate-derived mesenchymal stem cells attenuate hepatic steatosis via restoration of mitochondrial function Yun Bin Lee Received Received
  THU-070 Long-term outcome of symptomatic alcoholic hepatitis with a Maddrey discriminant function 32 Degré Delphine Received Received
  FRI-070 Circulating pcsk9 levels correlated with advanced disease in patients with biopsy-proven non- alcoholic fatty liver disease Sheila Gato Zambrano Received Received
  FRI-071 Non-invasive liver fibrosis markers, FIB-4, PRO-C3 and ADAPT, are significantly elevated in biopsy confirmed NAFLD patients at high risk of developing coronary heart disease and cardiovascular disease and are promising clinical decision making tools Samuel Daniels Received Received
  THU-071 Genetic variant PNPLA3 I148M accelerates fat accumulation in livers of mice with ASH/NASH via damping of PPAR alpha and PPAR gamma signalling pathways Eleonora Patsenker Received Received
  THU-072 Delisting of liver transplant candidates after improvement in alcohol-related decompensated cirrhosis: a multicentric study on incidence and outcomes Gonzalo Crespo Received Received
  FRI-073 Continuous CAP algorithm: reduced variability in a prospective cohort Anne LLORCA Received Received
  THU-074 Alcohol use disorder and liver fibrosis - cases are missed through failure to test Freya Rhodes Received Received
  FRI-074 Ultrasound small vessel imaging and deep learning; a novel approach to FLD screening Tim Hoogenboom Received Received
  THU-075 Decreasing incidence of alcoholic liver disease in Denmark: a nationwide study Frederik Kraglund Received Received
  FRI-075 Individual patient data meta-analysis on controlled attenuation parameter for the XL probe in obese patients Thomas Karlas Received Received
  THU-077 Mortality in biopsy-proven alcohol-related liver disease: population-based cohort study of 3,453 individuals Hannes Hagstrm Received Received
  SAT-077 Automated low flow ascites (ALFA) pump effectively reduces the number of large volume paracentesis - data from a real world cohort Adam Herber Received Received
  FRI-077 Optimal non-invasive screening strategy for non-alcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes Veeral Ajmera Received Received
  THU-078 Inhibition of cytochrome P-4502E1 by clomethiazole improves alcoholic liver disease in alcohol-dependent patients: a short-term, randomized, controlled clinical trial Helmut Seitz Received Received
  FRI-079 Use of the fibrosis-4 score to estimate fibrosis stage for patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in retrospective real-world datasets: a targeted literature review and feasibility assessment Elizabeth Artwick Received Received
  FRI-080 Obesity-specific health-related quality of life in patients with non-alcoholic steatohepatitis: results from the regenerate study Sari Rizk Received Received
  SAT-080 PPIs can be discontinued in over 60 of patients with cirrhosis: long term impact of screening for hepatitis C drug interactions Alison Boyle Received Received
  THU-081 In alcoholic hepatitis, cytokeratin 18 serum fragments reflect its severity and predict responsiveness to prednisolone JANE GROVE Received Received
  FRI-081 Significant knowledge gap about non-alcoholic fatty liver disease (NAFLD) in real-world practices: a global survey of hepatologists, gastroenterologists, endocrinologists and primary care physicians Carey Escheik Received Received
  FRI-082 A randomized, double blind, placebo-controlled trial of htd1801 (berberine ursodeoxycholate, budc ) in patients with hypercholesterolemia: implications for its use in non-alcoholic steatohepatitis (NASH) Jeffrey Dao Received Received
  SAT-082 Systemic inflammation is associated with cardiodynamic state in acute-on-chronic liver failure Sofia Monteiro Received Received
  SAT-083 Preliminary results of the effects of beta-hydroxy-beta-methylbutyrate supplementation in patients with liver cirrhosis: a randomized controlled pilot study Angelo Bruni Received Received
  THU-084 Pharmacokinetics of DUR-928 in alcoholic hepatitis patients - a phase 2a study Jaymin Shah Received Received
  FRI-084 Gw9662, a peroxisome proliferator-activated receptor gamma antagonist, attenuates the development of non-alcoholic fatty liver disease Anja Baumann Received Received
  SAT-084 Optimizing nutrition in patients with cirrhosis may reduce hospital readmissions in medium and high risk groups: a quality improvement project Angela Liaros Received Received
  SAT-085 Adipopenia, among the nutritional parameters, is the rapid screening tool that best correlates with mortality in decompensated cirrhotic patients: results of a prospective study Anna Lombardi Received Received
  FRI-085 Obesity management during the rise of NAFLD: real world outcomes of the medical weight loss approach using a very low energy diet Ann Farrell Received Received
  FRI-086 Supplementing diet with olive oil does not prevent the progression of non-alcoholic fatty liver disease Annette Brandt Received Received
  SAT-086 Leptin as a key player in insulin resistance of liver cirrhosis Anna Mrzljak Received Received
  SAT-087 Femur fractures are associated with high morbimortality in patients with cirrhosis Anna Brujats Received Received
  SAT-088 The presence of infection during hospitalization is associated with an increased risk of procedure-related bleeding in cirrhosis Abhishek Shenoy Received Received
  FRI-088 Single doses of TERN-201, a novel ive semicarbazide-sensitive amine oxidase (SSAO) inhibitor, are safe, well-tolerated, and result in sustained reduction of SSAO activity in healthy participants Martijn Fenaux Received Received
  SAT-089 Role of urinary neutrophil gelatinase-associated lipocalin, kidney injury molecule-1 and cystatin C as markers of mild kidney function impairment in patients with liver cirrhosis Anna Szymanek-Pasternak Received Received
  FRI-089 Decline in NASH and atherosclerosis-associated oxidised phospholipids and 7-ketocholesterol in response to icosabutate therapy David A. Fraser Received Received
  THU-090 High risk of futile over-referrals or late under-referrals among patients suspected of alcohol-related or non-alcohol-related fatty liver disease: real-world evidence reveal opportunities to optimize referral patterns to secondary care Katrine Prier Lindvig Received Received
  SAT-090 Analysis of factors associated with the prognosis of cirrhotic patients who were treated with V2-receptor antagonist for hepatic edema Koichi Takaguchi Received Received
  SAT-091 Combination of meld and lactates predicts early death in patients treated by salvage tips for refractory variceal bleeding Aurélie Walter Received Received
  THU-092 Differential roles of receptor interacting protein 3 and mixed lineage kinase like in murine models and patients with alcohol- and non-alcohol related liver disease Tatsunori Miyata Received Received
  SAT-092 Esophageal varices recurrence after eradication: are there any predictors ? Myriam Ayari Received Received
  SAT-095 Risk factors associated with mortality in upper gastrointestinal bleeding in cirrhotic patients Andra Barbulescu Received Received
  SAT-096 Epithelial cell death markers M65 and M30 are significantly up-regulated in decompensated liver cirrhosis and decreased by correction of portal hypertension Beatrice-Victoria Jahn Received Received
  FRI-096 A randomized, double-blind, placebo-controlled, first-in-human single ascending dose, multiple ascending dose, and food effect study to evaluate the safety, tolerability, and pharmacokinetic profile of FM101 in healthy volunteers Seon-Ah Ha Received Received
  SAT-097 Bidimensional shear wave elastography of the rectus femoris muscle in patients with cirrhosis Chiara Becchetti Received Received
  FRI-097 Direct access lifestyle training improves liver biochemistry and causes weight loss but uptake is suboptimal in patients with NAFLD Imran Patanwala Received Received
  SAT-099 Rotational thromboelastometry (rotem)-based assessment of coagulopathy in cirrhotic patients stratified by severity of portal hypertension Benedikt Simbrunner Received Received
  SAT-100 Impact of extended- spectrum- beta- lactamase faecal carrier on cirrhotic patients: a retrospective study on clinical outcomes before and after liver transplantation Bianca Magro Received Received
  FRI-100 Molecular, cellular, and pharmacological characterization of beta-ive partial agonists of human thyroid hormone receptor for the treatment of non-alcoholic steatohepatitis Jerome Deval Received Received
  THU-102 Shedding light on BASH: a novel experimental model of advanced liver damage Raquel Benedé Received Received
  SAT-102 Renal clearance measured by iohexol identifies cirrhotic patients with normal creatinine at risk of serious adverse events Carlos González-Alayón Received Received
  FRI-102 Efficacy and feasibility of a very low calorie diet to achieve 10 weight loss in patients with advanced non-alcoholic fatty liver disease Kate Hallsworth Received Received
  SAT-104 Impact of non-ive beta-blockers on hepatic encephalopathy in patients with liver cirrhosis Christian Labenz Received Received
  FRI-104 The effectiveness of Mediterranean diet versus calorie restriction in non-alcoholic fatty liver disease (NAFLD): a systematic review with clinical implications Laura Haigh Received Received
  SAT-105 Characterization of alterations in mechanical, thermal and pain sensitivity in cirrhotic patients with minimal hepatic encephalopathy Carmina Montoliu Received Received
  SAT-106 Role and prognostic value of routine doppler sonography in patients with severe liver disease - a prospective cohort study in an intensive care unit Constantin Maier-Stocker Received Received
  FRI-106 Endoscopic gastric plication (endosleeve) improves hepatic steatosis and liver fibrosis in patients with grade 1-2 obesity, preliminary results at 6 months Michel Ble Received Received
  SAT-107 Lack of evidence of significant tubular injury in patients with cirrhosis and persistent hepatorenal syndrome. implications for liver transplantation Cristina Solé Martí Received Received
  FRI-107 Use of GLP-1 receptor agonists (GLP1A) and/or SGLT-2 inhibitors (SGLT2I) in populations with NASH or at risk of NASH in US clinical practice Michelle Lai Received Received
  FRI-108 BIO89-100, a novel glycopegylated FGF21 analog, reduces body weight and fat mass in naive CD-1 mice through an increase in energy expenditure despite an increase in food consumption Moti Rosenstock Received Received
  SAT-108 Hepatic and splenic elastography: are they predictors of recurrence of esophageal varices after complete eradication? Daniela Reis Received Received
  THU-108 Plasma protein glycomics combined with circulating fragments of cytokeratin-18 are reliable biomarkers to diagnose alcoholic hepatitis Verhelst Xavier Received Received
  SAT-109 Risk of contrast-induced acute kidney injury in cirrhotic patients undergoing computed tomography: myth or reality? Daniela Campion Received Received
  THU-110 Single-cell analysis of self-antigen-specific CD4 T cells reveals the B helper signature and the peripheral reservoir of autoreactive T cells in autoimmune hepatitis Amédée Renand Received Received
  FRI-110 Characterization of EYP001 a novel, potent and ive FXR agonist in in vitro 3D human liver models of NASH Pauline RADREAU-PIERINI Received Received
  THU-111 FXR agonists repress innate and adaptive effector cytokine production in primary sclerosing cholangitis Astha Malik Received Received
  FRI-111 Synergistic effect of clostridium butyricum miyairi on rifaximin in mice model of non-alcoholic steatohepatitis by methionine choline-deficient diet Ryo Yamauchi Received Received
  FRI-113 Recombinant glutamine synthetase (AM-535): a novel therapeutic approach for the treatment of hyperammonaemia and its deleterious effects on multiple systems Antria Siakalli Received Received
  THU-113 Absence of BSEP (ABCB11) protects MDR2 (ABCB4) KO mice from cholestatic liver and bile duct injury through modulating hepatic and intestinal inflammatory signaling Claudia Fuchs Received Received
  THU-114 Predicted risk of end stage liver disease utilizing the UK-PBC risk score with continued standard of care and subsequent addition of obeticholic acid for 60 months in patients with primary biliary cholangitis Sari Rizk Received Received
  FRI-115 A randomized, double-blinded, placebo-controlled single ascending dose study to assess safety, tolerability, immunogenicity, and pharmacokinetics of a novel long-acting GLP-1/GIP/glucagon triple agonist (HM15211) in healthy obese subjects Seungjae Baek Received Received
  SAT-116 PROSPER study reveals reduction in bed days per hospitalisation and decreased risk of mortality for patients observed on rifaximin-alpha 550mg compared to a cohort on standard of care Dave Walker Received Received
  FRI-116 Change in hepatic output of palmitic acid after weight loss in type 2 diabetes Shaden Melhem Received Received
  THU-117 Metagenomic sequencing in primary sclerosing cholangitis highlights microbial metabolism of essential nutrients and multiple altered species Johannes R. Hov Received Received
  FRI-118 Long-term safety profile of cenicriviroc in adults with non-alcoholic steatohepatitis: rollover study Sven Francque Received Received
  SAT-118 Improving nutritional care in patients with liver cirrhosis: a quality improvement project Syazeddy Samani Received Received
  SAT-119 90-day mortality is lower after as compared to before transjugular intrahepatic portosystemic shunt at the same model for end-stage liver disease score Laurie Eicher Received Received
  FRI-119 Novel autophagy inducer, a4368 improves non-alchoholic steatohepatitis in mice Hyun Jin Jung Received Received
  THU-119 Negative immune regulator LNK/SH2B3 contributes to the development of autoimmune liver disease in mice under fatty-metabolic stress Taizo Mori Received Received
  THU-120 Mast cell activation mediates biliary immunobiology and subsequent immune response in a model of primary biliary cholangitis lindsey kennedy Received Received
  SAT-120 Long-term prospective study of development of hepatocellular carcinoma in compensated cirrhosis Alessandra Pivetti Received Received
  FRI-120 Intrahepatic microcirculation disorders and increased blood ammonia at the chronic liver diseases with initial stage of liver fibrosis Tatiana Ermolova Received Received
  THU-122 Klebsiella in the mucosal gut microbiota in primary sclerosing cholangitis is associated with more severe disease Mikal Jacob Hole Received Received
  THU-123 Downregulation of the bile acid receptor TGR5 in livers of PSC patients and ABCB4-/- mice Maria Reich Received Received
  SAT-124 Interest of echocardiography in the management of acute kidney injury in cirrhotic patients with ascites. Results of the prospective pilot cirren study Fanny Lebossé Received Received
  THU-124 Insufficient deletion of autoreactive CD4 T cells and plasticity of Tregs drive spontaneous autoimmune hepatitis in mice Max Preti Received Received
  FRI-124 Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on the alkaline phosphatase Alessio Gerussi Received Received
  FRI-126 Comparative effects of second-line therapy with obeticholic acid or fibrates in primary biliary cholangitis patients Anna Reig Received Received
  SAT-126 Head to head comparison of liver stiffness measurement using transient elastography, 2D-shear wave elastography and magnetic resonance elastography for non-invasive evaluation of clinical significant portal hypertension Filipe Andrade Received Received
  THU-126 Co-stimulatory molecules OX40 and CD30 mediates the regeneration of the liver epithelium in a mouse primary scletosing cholangitis model Naruhiro Kimura Received Received
  SAT-127 A hypercoagulable state does not play a major role in the development of portal vein thrombosis in patients with cirrhosis Fanny Turon Received Received
  FRI-127 Histological features of non-alcoholic steatohepatitis are common in patients with autoimmune hepatitis who have advanced fibrosis at diagnosis Michael Patrick Johnston Received Received
  SAT-128 Comparison of the diagnostic quality of aspiration and core biopsy needles for transjugular liver biopsy Georg Semmler Received Received
  FRI-128 Histological primary biliary cholangitis changes in patients with positive serology and normal alkaline phosphatase Benedetta Terziroli Received Received
  SAT-130 Ammonia is an independent biomarker of poor outcomes in patients with advanced cirrhosis Gonalo Alexandrino Received Received
  THU-130 Upregulation of hepatic TH17 response is associated with large duct disease and advanced hepatic fibrosis in pediatric autoimmune liver disease Simon Lam Received Received
  FRI-131 Psychometric evaluation of the adult itch reported outcome tool, a worst-itch numeric rating scale in adults with cholestatic liver disease Brandon Foster Received Received
  THU-132 Single cell RNA sequencing reveals naive T cells ready for effector function in livers of patients with primary sclerosing cholangitis Tobias Poch Received Received
  SAT-132 Risk stratification and the effects of early tips among patients with Child-Pugh B cirrhosis and acute variceal bleeding Guohong Han Received Received
  FRI-132 Effectiveness of obeticholic acid (OCA) in southern European patients with primary biliary cholangitis (PBC) as a second line therapy. A multicenter, international, real- world cohort Conrado Fernandez-Rodriguez Received Received
  SAT-133 Risk factors for sarcopenia and its impacts on clinical outcome in patients with liver cirrhosis Huijuan Xiao Received Received
  THU-133 Integrated analysis of GWAS and mRNA microarray identified IFN-? and CD40I as the central upstream-regulators in primary biliary cholangitis Kazuko Ueno Received Received
  FRI-133 Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 study Mary Standen Received Received
  THU-134 FcRL4 b cells are associated with inflamed bile ducts in patients with primary biliary cholangitis and locally capture IGA immune complexes Yuxin Liu Received Received
  FRI-134 Hepatocellular carcinoma in patients with autoimmune hepatitis: prevalence and risk factors Nayana Vaz Received Received
  SAT-134 The burden of cirrhosis on the Canadian healthcare system: a comparison between alcoholic and non-alcoholic cirrhosis patients Hassan Azhari Received Received
  SAT-136 Collagen type XVIII is associated with platelet count and meld score in patients with trans-jugular intrahepatic portosystemic shunt Ida Villesen Received Received
  SAT-137 Terlipressin vs noradrenaline for the treatment of hepatorenal syndrome in patients with acute-on-chronic liver failure: a 5-year retrospective analysis Ilaria Giovo Received Received
  THU-137 Acute kidney injury is associated with reversible platelet dysfunction in hospitalized patients with decompensated cirrhosis Alberto Zanetto Received Received
  SAT-138 Sarcopenia predicts mortality after transjugular intrahepatic portosystemic shunt creation in patients with refractory ascites Ioannis Petridis Received Received
  FRI-138 Poor diagnostic accuracy of blood igG4/igG RNA ratio for discriminating igG4-related disease from pancreatic or biliary cancer (DIPAC ): a prospective cohort study Elsemieke de Vries Received Received
  THU-138 Different inflammasome activation predisposes for acute-on-chronic liver failure depending on hepatic compensation in human and experimental liver cirrhosis Sofia Monteiro Received Received
  THU-139 Impaired splenic function in liver cirrhosis: a study in 69 patients with cirrhosis from outpatient hepatology clinic in a tertiary hospital in northern Greece Lamprini Kirkineska Received Received
  FRI-139 Glucuronidation directs systemically available norursodeoxcholic acid (norUDCA) to the kidney Michael Stie Received Received
  THU-140 Histological characterization of muscle and adipose tissue in patients with cirrhosis receiving liver transplant Maryam Ebadi Received Received
  FRI-140 Predictive factors of response to corticosteroid therapy in acute severe autoinmune hepatitis: a national multicentric study Eugenia Sánchez Rodríguez Received Received
  FRI-141 Antibodies against glycoprotein 2 and anti-neutrophil cytoplasmic antibodies targeting the serine proteinase 3 are markers of severe primary sclerosing cholangitis (PSC) and progression to cholangiocarcinoma (CCA) Ewa Wunsch Received Received
  THU-141 A genetic risk score predicts de novo hepatocellular carcinoma in hepatitis C cirrotic patients treated with direct-acting antivirals Elisabetta Degasperi Received Received
  THU-142 The bone marrow pool of megakaryocytes and their ability to proliferate are preserved in rats with advanced cirrhosis Iris Asensio Received Received
  FRI-142 Analysis of 1,776 patients with primary sclerosing cholangitis from a laboratory database Friedrich Mittermayer Received Received
  SAT-143 Microbiome metabolic therapies reduce microbiota-associated ammonia in ex vivo fecal samples from healthy subjects and patients with minimal hepatic encephalopathy and demonstrate improved tolerability over lactulose in a clinical study Robin Raskin Received Received
  THU-143 Bile acids modify ROS production, impair chemotaxis and delay apoptosis of neutrophils in vitro Irina Komarova Received Received
  SAT-144 KB174 reduces relative abundance of multidrug resistance (MDR) enterobacteriaceae in fecal samples from patients with cirrhosis in an ex vivo test system Robin Raskin Received Received
  FRI-144 Risks and benefits of percutaneous transhepatic cholangiodrainage in patients with primary sclerosing cholangitis Gustav Buescher Received Received
  SAT-145 Prevalence and clinical significance of portal vein thrombosis in cirrhotic patients with acute decompensation Yan Zhang Received Received
  FRI-145 Antimitochondrial antibodies in patients with autoimmune hepatitis: a large multicenter study Nikolaos Gatselis Received Received
  THU-146 SLU7 downregulation potentiates liver damage through hepatic de-differentiation María Gárate-Rascón Received Received
  FRI-146 Durability of biochemical improvements through six years of open label treatment with obeticholic acid in patients with primary biliary cholangitis who did not achieve the poise criteria Sari Rizk Received Received
  SAT-146 Pre-emptive (early) transjugular intrahepatic porto-systemic shunt in the treatment of high-risk acute variceal bleeding. An individual patient data meta-analysis Oana Nicoara Farcau Received Received
  SAT-147 Increased risk of perinatal complications in women with cirrhosis: a population-based matched cohort study Jennifer Flemming Received Received
  THU-147 Endotrophin predicts clinical outcome and mortality in patients with compensated cirrhosis Mette Juul Nielsen Received Received
  SAT-148 Does the wedge hepatic vein pressure estimates the portal pressure in patients with NASH cirrhosis? José Ferrusquía-Acosta Received Received
  FRI-148 An international perspective on cholestatic pruritus in primary biliary cholangitis (PBC) Helen Smith Received Received
  FRI-149 Magnetic resonance imaging features of primary biliary cholangitis Ilkay Idilman Received Received
  FRI-150 Comparison of liver stiffness measurement with MRE and liver and spleen volumetry for prediction of disease severity and hepatic decompensation in patients with primary sclerosing cholangitis Ilkay S. Idilman Received Received
  SAT-150 Prediction of variceal eradication in decompensated liver cirrhosis: a novel model Xing Wang Received Received
  FRI-151 The inter-relationship between primary sclerosing cholangitis and socioeconomic status Jessica Dyson Received Received
  THU-151 Hepatocytes undergo pyroptosis in response to lipopolysaccharide exposure, and can be sensitised to cell death by ER stress Ugo Soffientini Received Received
  SAT-151 A comparison of non-invasive methods for the screening of gastroesophageal varices in patients with compensated cirrhosis Jonathan Ng Received Received
  THU-152 Faecal cytokines provide novel insights into the role of gut mucosal inflammation in acute decompensation of cirrhosis Vishal C Patel Received Received
  SAT-152 Pre-procedural blood product transfusion and bleeding predictors in patients with chronic liver disease undergoing elective invasive procedures at a tertiary liver unit Jonathan Durbin Received Received
  FRI-154 The clinical significance of programmed cell death-1 rs11568821 and interleukin-28b rs12979860 polymorphisms in autommune hepatitis Kalliopi Azariadi Received Received
  SAT-154 Sarcopenia and liver cirrhosis: comparison of the European working group on sarcopenia criteria 2010 and 2019 Julia Traub Received Received
  SAT-155 Validation of diagnostic usefulness of the spot urine Na/K ratio for replacement of 24-hour urine NA excretion in cirrhotic patients with ascites Jinwook Lee Received Received
  THU-156 The role of urea on the prognosis of severe acute liver injury and acute liver failure Ana Craciun Received Received
  FRI-156 Maternal and foetal outcomes, biochemistry and immunology changes during pregnancy in patients with autoimmune hepatitis Kathryn Olsen Received Received
  SAT-156 Proton pump inhibitor use is associated with an increased risk of hepatic encephalopathy in a large cohort of patients with cirrhosis Koos de Wit Received Received
  THU-157 Idiosyncratic drug-induced liver injury in the elderly: an analysis of cases from the Spanish DILI registry Raul J. Andrade Received Received
  FRI-157 Impaired sulfation capacity may deteriorate clinical course in patients with primary sclerosing cholangitis (PSC) Karolina Maria Wronka Received Received
  SAT-157 Quality improvement campaign led to higher surveillance rate for hepatocellular carcinoma in primary care clinic Kanit bunnag Received Received
  THU-158 Use of the molecular adsorbent recirculating system in acute liver failure: a North American multicenter experience Andrew MacDonald Received Received
  SAT-158 Calf circumference as an easy surrogate marker for the screening of Japanese patients with chronic liver disease Kei Endo Received Received
  FRI-158 Accuracy of liver stiffness measurement in assessing liver fibrosis in naive patients with primary biliary cholangitis Laura Cristoferi Received Received
  THU-159 MELD score is the best predictor for transplant-free survival in patients with acute liver injury Carolina Simes Received Received
  FRI-159 Ciprofibrate: a new option of fibrate for primary biliary cholangitis with incomplete response to ursodeoxycholic acid Laura Guedes Received Received
  SAT-159 A novel method: can stapedial acoustic reflex have a role in the diagnosis of minimally hepatic encephalopathy? Bugra Tolga Konduk Received Received
  FRI-160 Utility of thiopurine metabolite testing in autoimmune hepatitis: defining an optimal therapeutic range for disease management and measurement may avert relapse and adverse drug reactions Lena Candels Received Received
  SAT-161 Validation of HCC risk calculator in a UK centre and implications of thresholds for screening Laura Atkins Received Received
  FRI-161 Correlation of serum bile acids and pruritus with aldafermin (NGM282) therapy in patients with primary sclerosing cholangitis Lei Ling Received Received
  THU-161 The therapeutic role of iNOS-expressed myeloid derived suppressor cells in acetaminophen induced acute liver failure Chien-Hao Huang Received Received
  SAT-162 Liver stiffness by transient elastography to detect porto-sinusoidal vascular liver disease in patients with portal hypertension Laure Elkrief Received Received
  SAT-163 The utilisation of palliative care in patients with end-stage liver disease Lauren Andersson Received Received
  FRI-163 Development and validation of a novel risk score predicting long -term survival in autoimmune hepatitis Maaike Biewenga Received Received
  THU-164 Ferroptosis related regulatory protein NCOA4 and its lncRNA-mRNA co-expression network in patients witn anti-tuberculosis drug-induced liver injury Jun Chen Received Received
  FRI-165 Understanding of central and peripheral fatigue in primary biliary cholangitis Naw April Phaw Received Received
  SAT-165 Continuous infusion of terlipressin for hepatorenal syndrome therapy: evaluation of efficacy and safety in real-life setting Fernanda S. Linhares Received Received
  FRI-166 Genetic variant c.711 in the hepatobiliary phospholipid transporter ABCB4 is associated with clinically relevant liver stiffness in chronic liver diseases Marcin Krawczyk Received Received
  FRI-167 Response to treatment in autoimmune hepatitis determines the health-related quality of life Maurice Michel Received Received
  SAT-167 A novel score to predict mortality after transjugular intrahepatic portosystemic shunt in patients with renal insufficiency Luisa Fuerschu Received Received
  FRI-168 Serum bile acid species are associated with liver fibrosis and clinical disease progression in patients with primary sclerosing cholangitis Jun Xu Received Received
  SAT-168 Differential activation of humoral compensatory mechanisms in distinct stages of portal hypertension Lukas Hartl Received Received
  THU-168 Novel in vivo tracing of the hepatocyte origin of extracellular vesicles in mice with experimental liver disease Elena Blázquez-López Received Received
  FRI-169 Removal of fibrosis-related genes identifies a hepatic gene expression signature that identifies canonical signaling pathways and is correlated with clinical outcomes in patients with primary sclerosing cholangitis Chuhan Chung Received Received
  SAT-169 Prospective study of magnetic resonance spectroscopy identifies specific metabolic changes in covert hepatic encephalopathy Nway Yadanar Tun Received Received
  SAT-170 Bacterial infections correlate with poor prognosis in cirrhosis independently from liver disease severity Maria Corina Plaz Torres Received Received
  FRI-170 Hepatic transcriptomic analysis identifies a mast cell gene expression signature that correlates with fibrosis stage and is prognostic in patients with primary sclerosing cholangitis Chuhan Chung Received Received
  THU-171 Human bone marrow mesenchymal stem cells small extract vesicles promote hepatocyte regeneration in acute liver failure Juan Gao Received Received
  SAT-173 Value of Hitachi shear wave elastography (SWE) for exclusion of esophageal varices in patients with compensated advanced liver disease Marcel Razpotnik Received Received
  FRI-173 Machine learning models accurately interpret liver histology and are associated with disease progression in patients with primary sclerosing cholangitis Vicki Mountain Received Received
  SAT-174 Factors associated with the presence of cirrhotic cardiomyopathy defined according to the new multidisciplinary diagnostic criteria Marcel Razpotnik Received Received
  THU-174 Outcomes following deceased and live donor liver transplantation for the indication of acute liver failure: a multicenter experience Ilker Turan Received Received
  FRI-174 CCL24 modulates fibrosis development in primary sclerosing cholangitis: correlation of human serum CCL24 levels with fibrosis markers and data from the Mdr2-/- mouse model. Arnon Aharon Received Received
  SAT-175 Prevalence of cirrhotic cardiomyopathy according to the old and new diagnostic criteria Marcel Razpotnik Received Received
  THU-175 Expression of microRNA-124 in Kupffer cells modulates liver injury Jinyu Wang Received Received
  FRI-175 Belimumab: a promising third line treatment option for refractory autoimmune hepatitis Pinelopi Arvaniti Received Received
  THU-176 Predictors of acute liver failure and death among patients with dengue-induced severe hepatitis Tongluk Teerasarntipan Received Received
  SAT-176 Diagnostic and prognostic role of presepsin in patients with cirrhosis and bacterial infection Marco Senzolo Received Received
  FRI-176 European Association for the Study of the Liver primary biliary cholangitis guideline clinical care standards: the patient experience as recorded by PBC Foundation app and International Patient Registry Robert Mitchell-Thain Received Received
  FRI-177 A multi-disciplinary approach to igG4 related disease aids in diagnosis and management Rory Peters Received Received
  SAT-177 Reduced efficacy of norfloxacin prophylaxis to prevent spontaneous bacterial peritonitis over time: a systematic review and meta-analysis Marcus Mcke Received Received
  THU-178 Deletion of XBP1 in liver parenchymal cells ameliorates acetaminophen (APAP)-induced hepatotoxicity via activation of IRE1alpha-JNK1-ATG5-dependent autophagy Hui Ye Received Received
  SAT-178 Risk assessment of clinically significant portal hypertension by means of hepatosplenic volumetry in compensated cirrhosis mario romero cristóbal Received Received
  FRI-178 Long-term prevalence of gastro-oesophageal varices in early primary biliary cholangitis patients with good response to treatment Toru Setsu Received Received
  SAT-179 Zinc deficiency in cirrhosis predicts hepatic decompensation and mortality Marta Hernández Conde Received Received
  FRI-179 Symptom burden in patients living with primary biliary cholangitis: indigenous Canadians report significantly higher PBC-40 quality of life scores Surain Roberts Received Received
  THU-180 The protective effects of a sense oligonucleotide drug targeting inducible nitric oxide synthase for a rat model of acute liver injury Richi Nakatake Received Received
  SAT-180 A nomogram as an indirect method to identify sarcopenia in patients with liver cirrhosis Marta Hernández Conde Received Received
  FRI-180 Efficacy and tolerance of obeticholic acid in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid in real life: interim analysis of the OCARELIFE study Sari Rizk Received Received
  SAT-181 Impact of beta blocker therapy on systemic inflammation stratified by hepatic venous pressure gradient response Mathias Jachs Received Received
  THU-181 Hasi-iquest: investigating viral etiologies of acute liver failure of unknown cause Nicolas Gille Received Received
  FRI-181 Lost in the system: identification of patients with undiagnosed primary biliary cholangitis Jorge Yebra Carmona Received Received
  SAT-182 Protective effects of statin therapy in liver cirrhosis are limited by the common SLCO1B1 variant Melissa Merkel Received Received
  FRI-183 Mesenchymal stem cells regulated DX5 - liver natural killer cells in rescuing acute-on-chronic liver failure murine Jing Xiong Received Received
  SAT-183 Shifting the focus of liver cirrhosis to prevention with the help of the SEAL program Michael Nagel Received Received
  THU-183 Investigation into the cut-off point for chronicity of drug-induced liver injury through metabolomic profiling Jia-bo Wang Received Received
  FRI-184 Selecting patients with decompensated cirrhosis and acute-on-chronic liver failure (ACLF) admitted to the intensive care unit for liver transplantation Sophie-Caroline Sacleux Received Received
  SAT-184 Algorithm to predict development of sarcopenia after transjugular intrahepatic portosystemic shunt in decompensated cirrhosis Michael Praktiknjo Received Received
  THU-184 Hepatic steatosis predicts fibrosis in long-term methotrexate use Marcel Tomaszewski Received Received
  FRI-185 Improving the survival rate of acute-on-chronic liver failure patients complicated with invasive pulmonary aspergillosis Danli Chen Received Received
  THU-186 A novel HER2-targeted liposomal formulation for reducing the risk of liposome-induced hepatotoxicity Sara De Martin Received Received
  THU-187 Combination of sivelestat and n-acetylcysteine alleviates the inflammatory response and exceeds standard treatment for acetaminophen-induced liver injury Sarah Raevens Received Received
  THU-188 GSDMD inhibitor necrosulfonamide protects mice from galactosamine/lipopolysaccharide-induced acute liver failure via pyrotosis pathway Yi-Long Wu Received Received
  THU-189 Administration of lactobacillus alleviates experimental NASH by reducing miR-21 in the liver André A. Santos Received Received
  FRI-189 The prevalence of multi-resistant bacterial infections in patients with decompensated cirrhosis admitted to the intensive care unit Fischer Petra Received Received
  SAT-189 Factor VIII/protein C and not ADAMTS13/VWF:Ag ratio is a prognostic risk factor for patients with cirrhosis and low MELD score Niccolò Bitto Received Received
  FRI-190 Acute-on-chronic liver failure as defined by the European (EASL-CLIF) versus North American (NACSELD) diagnostic criteria in their prediction of short-term prognosis in patients with decompensated cirrhosis admitted into hospital Florence Wong Received Received
  THU-190 Disease severity and proton pump inhibitor use impacts strongest on faecal microbiome composition in cirrhosis Angela Horvath Received Received
  FRI-192 Artificial liver support system in hepatitis B virus-related acute-on-chronic liver failure patients Qian Zhang Received Received
  SAT-193 Tunnelated peritoneal catheter versus large volume paracentesis for refractory ascites in cirrhosis: a randomized controlled trial Nina Kimer Received Received
  THU-193 Gut microbiota and metabolites associated with response to ursodesoxycholic acid in patients with primary biliary cholangitis Bin Gao Received Received
  THU-195 Microbiota modulates ischemia-reperfusion injury in mouse liver transplantation Shoichi Kageyama Received Received
  FRI-195 Refining the renal failure criteria of the EASL-CLIF diagnostic model for defining acute- on- chronic liver failure (ACLF) Joana Calvão Received Received
  SAT-196 Efficacy of transjugular intrahepatic porto-systemic shunt in cirrhotic patients with hepatorenal syndrome - chronic kidney disease Paola Ponzo Received Received
  THU-197 Transplantation of gut microbiota derived from MCJ-KO genotype determines a protective profile against non-alcoholic fatty liver disease in germ-free mice David Porras Received Received
  SAT-197 The prevalence of esophageal varices needing treatment depends on gender, etiology and BMI Paul Cales Received Received
  FRI-197 Thymosin alpha 1 for patients with hepatitis B virus-related acute-on-chronic liver falure: a randomized controlled trial Jun-feng Chen Received Received
  FRI-198 Derivation and validation of prognostic nomogram for HBV-related acute-on-chronic liver failure Jun-feng Chen Received Received
  SAT-198 Direct acting oral anticoagulant use in cirrhosis patients: real-world bleeding and discontinuation rates Patrick Northup Received Received
  SAT-199 Fluency is associated with hepatic encephalopathy using a common and easy language task Patricia Bloom Received Received
  THU-199 Investigation of microbiome metabolites and mitochondrial function in non-alcoholic fatty liver disease Paula Boeira Received Received
  SAT-200 A smartphone app is feasible for outpatient ascites management Patricia Bloom Received Received
  FRI-200 Mesenchymal stem cells regulate hepatocytes excessive autophagy and apoptosis through miR-125b/TRAF6 pathway in acute- on- chronic liver failure Dengna Lin Received Received
  THU-200 Veillonella as a bile acid-sensitive bacteria and a microbiome-based biomarker for aldafermin (NGM282) in patients with non-alcoholic steatohepatitis Rohit Loomba Received Received
  SAT-201 Comparative study between spontaneous fungal peritonitis and spontaneous bacterial peritonitis in patients with end stage liver disease Mohamed Elnadry Received Received
  SAT-203 Sarcopenia increases the risk of post transjuglar intrahepatic portosystemic shunt hepatic encephalopathy Puja Bhatia Kapoor Received Received
  THU-204 Identification of gut bacterial candidates involved in hepatic encephalopathy by the analysis of feces DNA from patients administered rifaximin Yoshimi Muto Received Received
  FRI-204 Different transcriptome characteristics of peripheral blood mononuclear cells are associated with survival outcome in hepatitis B-related acute-on-chronic liver failure Shanshan Ma Received Received
  FRI-205 Granulocyte colony-stimulating factor in acute-on-chronic liver failure: systematic review and meta-analysis Rosa Martin- Mateos Received Received
  FRI-206 Dysfunctional adaptive immunity in liver cirrhosis and acute-on-chronic liver failure is characterized by aberrant immune checkpoint expression and diminished cytokine secretion in T cells Sabrina Rueschenbaum Received Received
  THU-207 Primed liver regeneration in protein convertase subtilisin/kexin type 9 knockout mice is associated with increased lipids uptake and hypercholesterolemia Jacopo Gavini Received Received
  SAT-207 Long-term 20 albumin administration normalizes the plasma albumin binding capacity in patients with decompensated cirrhosis Raquel Horrillo Received Received
  SAT-208 Aminoglycosides and metronidazole for the treatment of hepatic encephalopathy in adults with cirrhosis Rebecca Jeyaraj Received Received
  FRI-208 Serum cholinesterase, an underestimated marker in the prediction of acute-on-chronic liver failure, organ failure and LTx -free survival in patients with liver cirrhosis? Tammo Lambert Tergast Received Received
  SAT-209 Spleen stiffness and liver stiffness for predicting high risk varices in patients with compensated liver cirrhosis Renata Fofiu Received Received
  SAT-210 Natural history and outcomes of patients with liver cirrhosis complicated by hepatic hydrothorax Sarah Romero Received Received
  THU-210 Dynamic characterization of revascularization in decellularized whole-liver scaffold Jun Li Received Received
  FRI-210 Single- centre experience of implementing a hepatology outreach service to improve patient care for emergency admissions of acutely decompensated cirrhosis Tomi Ashaye Received Received
  SAT-211 Acute or recent portal vein thrombosis in cirrhosis predicts a hidden or upcoming diagnosis of hepatocellular carcinoma Rifaat Safadi Received Received
  THU-211 Optimal liver metabolism and proliferation require the tight junction protein claudin-3 Felix Alexander Baier Received Received
  FRI-212 Clinical features and natural history of acute-on-chronic liver failure precipitated by any indeterminate factor: single-center observational study Hitomi Hoshi Received Received
  THU-213 Serum transferrin levels reflect hepatocyte nuclear factor 4 alpha activity in the liver Nurdan Gldiken Received Received
  SAT-213 A prospective evaluation of the Bristol prognostic score: poor sensitivity and specificity in a non-Bristol cohort Sarah Bowers Received Received
  FRI-214 Baseline demographics and clinical characteristics of subjects enrolled in the phase 3 AURORA study of cenicriviroc for the treatment of liver fibrosis associated with non-alcoholic steatohepatitis Naim Alkhouri Received Received
  SAT-215 Diagnostic performance of contrast-enhanced CT for the diagnosis of portosinusoidal vascular disease: a case-control study Shantha Valainathan Received Received
  FRI-215 Diagnostic accuracy of a pocket-size ultrasound device in identifying liver surface nodularity for fibrosis staging in chronic liver disease Andrea Costantino Received Received
  FRI-216 Combination of an acetyl CoA carboxylase inhibitor with therapeutics that promote fatty acid oxidation moderately improves efficacy in a preclinical NASH model ARCHANA VIJAYAKUMAR Received Received
  SAT-217 A nurse-led albumin infusion service reduces the need for therapeutic paracentesis in the outpatient day procedure setting Siddharth Sood Received Received
  SAT-218 Increased levels of soluble mannose receptor are associated with poor outcome in cirrhosis: results from a 2-year longitudinal study Signe Wiese Received Received
  SAT-219 MRI-derived myocardial extracellular volume is closely associated with markers of collagen formation in cirrhosis Signe Wiese Received Received
  THU-221 Parenchyma-sparing hepatectomy improves salvageability and survival for solitary small intrahepatic cholangiocarcinoma Hui Li Received Received
  THU-222 Reducing length of stay in patients following a liver transplant Abdulrhman Alamr Received Received
  FRI-222 Enigma proteins control YAP1 related mechano-transduction in hepatic stellate cells Dina Abdelmottaleb Received Received
  SAT-222 Etiology and diagnosis of ascites: contemporary cohort study in a secondary care setting Mohsan Subhani Received Received
  FRI-224 The IL-17a and IL-22 cytokines like triggers of human liver fibrosis Daria Kartasheva-Ebertz Received Received
  SAT-224 Impact of acute decompensation on prognosis in patients with hepatocellular carcinoma Takayuki Kondo Received Received
  SAT-225 Serum cholinesterase is an independent predictor of hepatic encephalopathy, acute-on-chronic liver failure and mortality after transjugular intrahepatic portosystemic shunt insertion in patients with liver cirrhosis Lena Thle Received Received
  FRI-225 Fib-4 score for assessment of liver fibrosis is useful in general practice Denis Ouzan Received Received
  FRI-226 Analysis of PNPLA3 SNP variants in human hepatic stellate cells in 3D human liver extracellular matrix scaffolds reveals key PNPLA3-dependent pro-fibrogenic features Elisabetta Caon Received Received
  SAT-226 Transjugular intrahepatic portosystemic shunt in cirrhotic elderly patients with refractory ascites - to do or not to do? Lena Thle Received Received
  FRI-227 An HSV-TK / valganciclovir mouse model enables the study of fibrocytes in liver fibrosis Felix Hempel Received Received
  SAT-227 Four weeks of aerobic and resistance training improves frailty in patients with liver cirrhosis-liver habilitation (Li-Hab) center outcome data Varsha Shasthry Received Received
  THU-227 A new score including anthropometric measurement for weight improved prediction of mortality in adolescents on the liver transplantation waiting list: a US nationwide study Abdel Aziz Shaheen Received Received
  SAT-228 Effect of rivaroxaban on hypercoagulopathy risk factors in liver cirrhosis patients with nonvalvular atrial fibrillation Nataliya Virstyuk Received Received
  THU-228 Post-transplant lymphoproliferative disease after adult liver transplantation has a higher incidence after primary sclerosing cholangitis and can be prevented by surveillance of Epstein-Barr viral load with a pre-emptive strategy - a long-term study Bastian Ruijter Received Received
  THU-229 De novo metabolic syndrome after liver transplantation: a prospective, longitudinal study Chiara Becchetti Received Received
  SAT-229 Between rapid diagnosis and prediction of survival in minimal hepatic encephalopathy Vlad Taru Received Received
  FRI-230 TGF-beta3 plays a prominent role in murine parenchymal liver fibrosis Hiroyuki Abe Received Received
  SAT-231 Test-retest reliability of hepatic venous pressure gradient: a study in 215 patients from the control arms of 17 randomized controlled trials Wayne Bai Received Received
  FRI-232 Thrombofibrosis: inherited thrombophilia as a cause of significant liver fibrosis Iranzu Ezcurra Received Received
  FRI-234 An improved method for liver fibrosis assessment using magnetic resonance elastography JunSheng, Jaryl Cheng Received Received
  THU-234 Severe obesity increases death and dropout from liver waiting list: French liver transplant cohort Claire Delacte Received Received
  FRI-235 Expression of cyclin E1 and CDK2 in hepatic stellate cells is critical for initiation and progression of liver fibrosis in mice Julia Hennings Received Received
  SAT-235 Early albumin improves survival in cirrhotic patients on diuretic therapy who develop significant acute kidney injury: real-world evidence in the United States Santosh Telang Received Received
  FRI-236 Non-canonical autophagy in myeloid cells constrains hepatic and systemic inflammation and limits fibrosis JingHong Wan Received Received
  SAT-236 Test-retest reliability of hepatic venous pressure gradient: a study in 215 patients from the control arms of 17 randomised controlled trials Wayne Bai Received Received
  THU-236 Liver transplantation assessment: what are the factors associated with contraindication for listing or delayed activation on waiting list? Domitille Erard-Poinsot Received Received
  THU-237 Anticoagulation in liver transplant candidates: a case control study Domitille Erard-Poinsot Received Received
  FRI-237 Reduction in types I and III collagen gene expression by an alphavbeta1 integrin inhibitor correlates with a decrease in PRO-C1 and PRO-C3 levels in precision-cut liver tissue slices from cirrhotic non-alcoholic steatohepatitis patients Johanna Schaub Received Received
  SAT-237 Prognosis of alcoholic or viral B/C cirrhosis according to ABO blood group: results of abocirralvir, from CIRRAL and ANRS CO12 CirVir cohorts Isabelle Ollivier-Hourmand Received Received
  THU-238 Pre-transplant sarcopenic obesity worsens the survival after liver transplantation: a meta-analysis and systematic review Péter Hegyi Received Received
  FRI-238 Active role of sphingosine-1-phosphate in promoting peripheral-dominant liver fibrosis in mice model of congestive hepatopathy Hironari Kawai Received Received
  FRI-239 CRV431 decreases diet- and chemical-driven fibrosis in livers of mice Joseph Kuo Received Received
  SAT-240 Repeated versus single treatment of esophageal variceal ligation after esophageal variceal bleeding Young Youn Cho Received Received
  FRI-240 Fibrosis progression in NASH: real- world data from the US population LEONARDO RUIZ CASAS Received Received
  THU-241 Postreperfusion biopsy as predictor of outcomes after liver transplantation Esteban Fuentes Valenzuela Received Received
  FRI-241 Nanoparticular bisphosphonate induces an anti-fibrotic response by modulation of fibrosis associated genes and pathways in (non-) parenchymal liver cells in CCL4 fibrotic mice Leonard Kaps Received Received
  SAT-242 The predictive value of MRI-based markers of liver disease on clinical outcomes in patients with cirrhosis Christina Levick Received Received
  SAT-243 Elast q - 2D shear wave liver elastography correlates well with vibration controlled transcient elastography in patients with different etiologies of chronic liver disease David JM Bauer Received Received
  THU-245 Early versus late hepatocellular carcinoma (HCC) recurrence after liver transplantation for HCC: patterns and long-term outcome Faouzi Saliba Received Received
  FRI-245 Epigenetic mechanism and metabolic reprogramming in fibrogenesis: dual targeting of G9a and DNA methyltransferase 1 for the inhibition of liver fibrosis Maite G Fernandez-Barrena Received Received
  SAT-246 Endothelin-1 level at first presentation of hematemesis as indicator of recurrent bleeding within 5 days Ahmed Ibrahim Received Received
  THU-250 Survival after liver transplant in recipients of different age groups: a systematic review and meta-analysis Ho Ming CHENG Received Received
  SAT-250 Breath-based monitoring of liver metabolism using exogenous volatile organic compounds - towards improved detection Giuseppe Ferrandino Received Received
  FRI-250 Hepatocytic C-jun NH2 terminal kinase activity confers protection against cholestatic liver injury in mice Mohamed Ramadan Mohamed Received Received
  THU-251 Prophylactic rifaximin use in liver transplant candidates is associated with false positive results of the alcohol biomarker, ethyl sulphate Ian Webzell Received Received
  THU-252 Predictive factors of symptomatic nodular regenerative hyperplasia after liver transplantation Ilias Kounis Received Received
  FRI-253 Non-invasive test cut-offs for the identification of advanced liver fibrosis in a diabetes cohort with non-alcoholic steatohepatitis: data from the phase 3 AURORA study Quentin M Anstee Received Received
  SAT-254 Serum keratin 19 (CYFRA 21-1) links ductal reaction with portal hypertension and outcome of advanced liver disease Karim Hamesch Received Received
  THU-254 Long-term outcomes of persistently positive hepatitis B surface antigen after liver transplantation for chronic hepatitis B James Fung Received Received
  SAT-255 Relationship between Laennec histological subclassification of cirrhosis and clinical stage, grade of portal hypertension and liver stiffness Lejealle Clement Received Received
  THU-257 Hepatitis B immunoglobulin prophylaxis for prevention of de novo Hepatitis B infection from hepatitis B core antibody-positive donors Kyeongdeok Kim Received Received
  SAT-258 Systemic light chain AL with cardiac and liver involvement can be predicted by transient elastography Speranta Iacob Received Received
  FRI-258 Aldafermin (NGM282) reduces the cross-linked pro-peptides of type III collagen PRO-C3X, a novel biomarker, in non-alcoholic steatohepatitis and primary sclerosing cholangitis patients Stephen A. Harrison Received Received
  FRI-262 (pro)renin receptor knockdown attenuates liver fibrosis through inactivation of ERK/TGF- ?1/Smad3 pathway Yun-Cheng Hsieh Received Received
  THU-262 Portal venous thrombosis and liver transplant: incidence and evolution in the 1st year after transplant MARIA ANGELES LOPEZ GARRIDO Received Received
  THU-263 Utility of anticoagulation in portal venous thrombosis before and after liver transplant MARIA ANGELES LOPEZ GARRIDO Received Received
  SAT-263 Liver stiffness measurement using acoustic radiation force impulse elastography is a good predictor of hepatic decompensation in pregnant cirrhotic patients Omar Elshaarawy Received Received
  THU-264 Safety and efficacy of a cardiac risk stratification protocol based on traditional cardiac risk-factors in patients undergoing liver transplantation Marcus Robertson Received Received
  FRI-264 Improvements in the ELF test are associated with widespread changes in the hepatic transcriptome in patients with advanced fibrosis due to non-alcoholic steatohepatitis Marianne Camargo Received Received
  SAT-264 Reliablility criteria will discriminate accuracy of blood liver fibrosis tests Paul Cales Received Received
  SAT-265 The usual blood liver markers provide a performant fibrosis test thanks to artificial intelligence Paul Cales Received Received
  THU-265 Projection of liver transplant activity per indication in France and United Kingdom Mark Connolly Received Received
  FRI-265 Contrast-enhanced ultrasound algorithms for the non-invasive diagnosis of hepatocellular carcinoma in high-risk patients - a prospective multicentre study (DEGUM-CEUS HCC trial) Barbara Schellhaas Received Received
  SAT-266 A gut microbiota and liver co-metabolized biomarker to monitor liver cirrhosis progression with different etiologies in humans Jia-bo Wang Received Received
  THU-266 The impact of gender and comorbidity burden on liver transplant eligibility and patient survival Marwan Ghabril Received Received
  SAT-267 Serum metabolic biomarkers for the differential diagnosis of distal cholangiocarcinoma and pancreas ductal adenocarcinoma Rocio IR Macias Received Received
  THU-268 Accuracy of triple echo MRI in predicting hepatic steatosis in potential liver donors Mohammed Aljawad Received Received
  SAT-268 Proteomic identification of serum factors that correlate with reduction of HVPG following curative treatment for hepatitis C virus infection shola richards Received Received
  FRI-269 Ph-responsive polymersomes for matrix metalloproteinase-1 delivery as a promising therapeutic strategy for the treatment of liver fibrosis Eline Geervliet Received Received
  THU-270 Positive complement-dependent cytotoxicity crossmatch results do not influence long-term graft or patient survival following liver transplantation Neil Halliday Received Received
  SAT-270 Virtual touch quantification using acoustic radiation force impulse technology versus transient elastography for the non-invasive assessment of liver fibrosis in patients with chronic hepatitis B or C using liver biopsy as gold standard Baldea Victor Received Received
  SAT-271 Quantitative magnetic resonance cholangiopancreatography imaging in patients with primary sclerosing cholangitis - feasibility and preliminary analysis for prediction of clinical outcomes VIjay Are Received Received
  THU-272 Clostridium difficile infection in liver transplant recipients is uncommon and does not impact long-term survival: a case-control study Nicholas Kortt Received Received
  SAT-272 Two-dimensional real-time shear wave elastography and risk for de novo hepatocellular carcinoma in patients with advanced chronic liver disease Wenyi Gu Received Received
  SAT-273 Progress in hepatitis C testing as a part of the hepatitis C elimination program in Georgia Amiran Gamkrelidze Received Received
  FRI-273 Kahweol activates Nrf2/HO-1 by a pathway different from p62 and autophagy dependent degradation Byoung Kuk Jang Received Received
  FRI-274 Role of Kupffer phase image using sonazoid on CEUS LI-RADS and diagnostic performance for hepatocellular carcinoma Jeong Ah Hwang Received Received
  THU-274 Patient social and lifestyle factors associated with cardiovascular risk affect decisions regarding transplant candidacy more than factors associated with psychological and financial well-being Oliver Tavabie Received Received
  THU-275 Inequality in access to liver transplant: are satellite liver transplant centres the answer? Oliver Tavabie Received Received
  FRI-275 Impact of contrast-enhanced ultrasound on detection of colorectal liver metastases and therapeutic strategy in patients with newly diagnosed colorectal carcinoma after staging with computertomography. A prospective cohort study Mikael Sawatzki Received Received
  SAT-275 HCV in addiction care: different epidemiology, excellent treatment results Andrea Afonso Díaz Received Received
  FRI-276 The phenotype of compound heterozygous BSEP deficiency patients is determined by the combined residual function of the two ABCB11 mutations: results from the NAPPED consortium Antonia Felzen Received Received
  SAT-277 The best strategy for retrieval of hepatitis C patients lost to follow up: randomized clinical trial Alberto Hernández Bustabad Received Received
  THU-277 Poor dental health is a risk factor for infections by streptococci after liver transplant Philipp Lutz Received Received
  FRI-277 Proteostasis improvement in cystic cholangiocytes alleviates endoplasmic reticulum stress and halts polycystic liver disease Alvaro Santos-Laso Received Received
  SAT-278 Is hospital admission an ideal condition for HCV screening? A survey from the Venetian area (north-east of Italy) Alessandro Caroli Received Received
  FRI-281 ABCB4/MDR3 gene mutations in young patients with symptomatic cholelithiasis Catarina Gouveia Received Received
  SAT-281 Role of immigration in chronic HBV and HCV infection in our environment. Origin and characteristics of the patients Ángela Suárez-Noya Received Received
  THU-281 Incidence and prognostic impact of cancer after liver transplantation Manuel Rodríguez-Perálvarez Received Received
  THU-282 Gender disparity in cardiovascular morbidity and mortality post liver transplantation Samarth Patel Received Received
  SAT-282 From stagnation to elimination: tracking hepatitis C elimination policy implementation in Europe in partnership with patient organizations Adam Palayew Received Received
  THU-284 Is hepatitis B immunoglobulin necessary for hepatitis D prophylaxis after liver transplantation? A retrospective multicenter study of a cohort of 174 patients Sergio Rodriguez Tajes Received Received
  FRI-284 Impact of nitisinone treatment and discontinuation on the metabolome of wild type and hereditary tyrosinemia type 1 mice Haaike Colemonts-Vroninks Received Received
  SAT-284 Treatment cascade of hepatitis C in a non-university hospital setting, that uses a hub-and-spoke model, in southern Switzerland Adriana Baserga Received Received
  FRI-285 Prognosis in persons with an HFE-mutation: population-based cohort study of 3,645 individuals Hannes Hagstrm Received Received
  THU-285 Pre-transplant diabetes independently predicts atherosclerotic vascular event and death due to cardiovascular disease in liver transplant recipients: a long term multicenter observational study Margherita Falcini Received Received
  SAT-285 A nurse led hepatitis C model of care in primary care and community services in Melbourne, Australia Brendan Harney Received Received
  SAT-286 Barriers to hepatitis C virus elimination in Germany: why arent diagnosed patients initiating therapy? Jeff Lehman Received Received
  THU-287 Improvement of renal function prior to liver transplantation is not associated with better long-term renal outcome or mortality Thomas Horvatits Received Received
  THU-288 An open-label, cohort study of grazoprevir/elbasvir combination therapy for patients with genotype 1b chronic hepatitis C after liver or kidney transplantation Teng-Yu Lee Received Received
  SAT-288 Description of HBV-infected persons presenting late to specialist care in 10 Spanish centres: A retrospective registry review Camila A Picchio Received Received
  SAT-289 The prevalence of hepatitis C amongst people who use performance and image enhancing drugs - a systematic review Charlotte Cook Received Received
  FRI-289 Directed protein evolution as a tool to innovate gene therapy for hereditary tyrosinemia type 1 Jessie Neuckermans Received Received
  THU-290 Usefulness of the AFP model to predict recurrence tumor in patients transplanted with carcinoma hepatocellular within Milan criteria Víctor Jiménez Beltrán Received Received
  SAT-291 Hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington, USA Maria Corcorran Received Received
  THU-291 Therapy with DAA increases post-OLT survival but not the risk of recurrence in patients undergoing liver transplantation for HCV-related HCC Vito Sansone Received Received
  FRI-292 Genome-wide protective variants in MARC1 and HSD17B13 are associated with reduced inflammation and lower fibrosis stage on biopsy in children with NAFLD Jake Mann Received Received
  SAT-292 Dried blood spots are a useful tool for hepatitis A screening in the pandemic areas with medical resource-limited condition Chikako Yamamoto Received Received
  THU-292 Geographic disparities and socioeconomic determinants in liver transplantation referral at the Scottish Liver Transplant Unit Wilson Siu Received Received
  SAT-293 Viral hepatitis in Belgian prisons: a first-time multicenter prevalence study Dana Busschots Received Received
  THU-293 Pre-operative biliary drainage in perihilar cholangiocarcinoma: an overview of systematic reviews Xinwei Chang Received Received
  SAT-294 Limburg is the first Belgian province on track for hepatitis C virus eradication in the most important group at risk: People who use drugs Dana Busschots Received Received
  THU-294 Imprints of post-liver transplantation: HCV recurrence on immune cell compartment persist despite achieving therapy-induced SVR Amare Aregay Received Received
  FRI-294 Cholestatic phenotype of a mouse model for organic solute transporter ? (OST?/SLC51B) deficiency suggest a role of the beta subunit beyond an OST? chaperone Stan van de Graaf Received Received
  SAT-295 Early treatment of hepatitis C virus improves health outcomes and yields cost-savings: A modeling study in Argentina Diego Kanevsky Received Received
  FRI-295 Comparative pharmacokinetic profile of two distinct trientine salt formulations used for treatment of Wilsons disease Henry Abela Received Received
  FRI-296 Differential expression of bile acid subspecies with maralixibat treatment in pruritus responders with bile salt export pump deficiency Kenneth Setchell Received Received
  SAT-296 Tailored message interventions promote the number of participants in viral hepatitis screening for Japanese workers - multicenter trial of 1,127,596 general checkup applicants Masaaki Korenaga Received Received
  SAT-297 Data from a large, public sector hepatitis C program in Punjab, India Sajal Marwaha Received Received
  FRI-297 Clinical, histological, and biochemical liver phenotype of European adults with heterozygous alpha-1 antitrypsin deficiency (PiMZ genotype) Karim Hamesch Received Received
  THU-297 Hepatic ischemia induces a time-dependent increase in SERPINB3 gene expression CLARISSA BERARDO Received Received
  FRI-298 Customized xenograft model development: liver repopulation of FRG KO mice with primary hepatocytes from donors carrying specific genetic variants LANDER FOQUET Received Received
  SAT-298 Implementation of electronic monitoring and evaluation system for hepatitis C in Punjab, India Sajal Marwaha Received Received
  FRI-299 Alpha-1-antitrypsin deficiency liver disease: patients lost in the system Maria Angeles Ruiz-Ramirez Received Received
  FRI-300 Neurodegenerative patterns in Wilsons disease with hepatic or neurological manifestation assessed by morphometric magnetic resonance imaging Marlene Panzer Received Received
  SAT-300 Unusual occurrence of hepatitis B infection in Upper Egypt Mahmoud S. Elzalabany Received Received
  FRI-301 Liver transplantation for acute intermittent porphyria in Europe Mattias Lissing Received Received
  FRI-302 Magnetic resonance iron quantification facilitates venesection decision making in iron overload Meha Bhuva Received Received
  SAT-302 Classifying people living with hepatitis C virus using a population-level latent class analysis to inform optimal integration of health services Emilia Clementi Received Received
  FRI-303 Major depressive disorder in patients with Wilsons disease: relationship with liver disease, neurological disease and quality of life Michelle Camarata Received Received
  FRI-304 Mortality in patients with Wilsons disease in England: a national register-based study Michelle Camarata Received Received
  SAT-304 Hepatitis C virus testing and treatment in children: results from a global paediatric policy review Farihah Malik Received Received
  THU-304 Serum glycomics early after liver transplantation relate to graft loss 3 months after liver transplantation independently of early allograft dysfunction Verhelst Xavier Received Received
  SAT-306 Relationship between metabolic syndrome and ALT level with normal range in the general population Won Sohn Received Received
  FRI-307 Validation of the new proposed histological criteria for the diagnosis of porto-sinusoidal vascular disease in a single tertiary center Oana Nicoara-Farcau Received Received
  SAT-307 Are UK NAFLD/NASH referral pathways ready to tackle the emerging epidemic? A rapid systematic public health evidence synthesis Hannah Pheasant-Oldfield Received Received
  THU-308 Unravelling the molecular determinants of metabolic syndrome thanks to NMR-metabolomics of urine and serum samples Chiara Bruzzone Received Received
  FRI-308 Non-invasive diagnostic tools in porto sinusoidal vascular liver disease. A pilot study Oana Nicoara Farcau Received Received
  SAT-309 Opportunities to enhance linkage to hepatitis C care among people hospitalised for injection drug use-related complications: a population-based study Heather Valerio Received Received
  THU-309 The hedgehog effect: mediating crosstalk between liver and adipose tissue Fritzi Ott Received Received
  SAT-310 Searching for patients lost in the system with chronic hepatitis C in a tertiary hospital: a problem still to be solved Irene Andaluz Received Received
  FRI-311 Good clinical outcomes after direct intrahepatic portocaval stent (DIPS) insertion for Budd-Chiari syndrome Rosemary Faulkes Received Received
  SAT-311 Economic evaluation of the hepatitis C virus screening and treatment program in Georgia Irina Tskhomelidze Received Received
  FRI-312 Clinical features and natural history of 1154 Alagille syndrome patients: results from the international multicenter GALA study group Shannon M. Vandriel Received Received
  THU-312 Decreased expressions of p70S6K in NK cells of F4-NAFLD patients inhibited F-actin and was correlated with their impaired function Johnny Amer Received Received
  THU-313 A fatty acid amide hydrolase inhibitor, URB597, inhibits MICA and MICB shedding Kazuma Sekiba Received Received
  FRI-314 Wilsons disease: epidemiologic and therapeutic insights from German hospital and ambulatory invoicing data Steffen Wahler Received Received
  SAT-314 Do countries have the right policies to eliminate viral hepatitis B and C: a secondary analysis of the Lancet GastroHep viral hepatitis commission Jeffrey Lazarus Received Received
  SAT-315 Validation of a novel rapid point-of-care ALT test in patients with viral hepatitis Jess Howell Received Received
  THU-316 The FXR agonist obeticholic acid decreases matrix metalloproteinase activity via RECK and TIMP modulation in hepatic ischemia/reperfusion injury Laura Giuseppina Di Pasqua Received Received
  SAT-316 Cost-effectiveness of screening and treatment using direct-acting antivirals for chronic hepatitis C virus in low- and middle-income settings JOSEPHINE WALKER Received Received
  FRI-316 Elevated serum bile acid and alanine aminotransferase concentrations in intrahepatic cholestasis of pregnancy are associated with increased fetal NT-proBNP which is ameliorated by ursodeoxycholic acid treatment Tharni Vasavan Received Received
  SAT-317 Cross-sectional associations between suspected non-alcoholic fatty liver disease, diabetes, and hypertension in hispanic adults living in the San Juan metropolitan area Josheili Llavona Received Received
  THU-317 Cross-linking of liver metabolism - hedgehog as a key regulator of energy metabolism, regulating mechanistic target of rapamycin activity Luise Spormann Received Received
  SAT-318 HCV care cascade of PWID enrolled in methadone substitution treatment program in Georgia - is this the first group of population in which hepatitis C will be eliminated in Georgia? Ketevan Stvilia Received Received
  THU-318 Functional consequences of metabolic zonation in murine livers: new insights for an old story Madlen Matz-Soja Received Received
  FRI-318 Prevalence and characteristics of cystic fibrosis associated-liver disease in a cohort of cystic fibrosis patients Zaina Issa Received Received
  FRI-319 Liver cirrhosis development and value of transient elastography among a large cohort of Wilsons disease patients with a long-term follow-up in Spain Zoe Mariño Received Received
  THU-319 PXB-cells for the study of lipid metabolism: robust and human-specific lipid profile in human hepatocytes freshly isolated from chimeric mice with humanized liver Masaki Takahashi Received Received
  SAT-320 Frequency of prenatal hepatitis C screening and diagnosis in British Columbia, 2008-2018 Margo Pearce Received Received
  SAT-321 Re-capturing a lost population - the benefits of a nurse-delivered HCV community cirrhosis clinic Maryam Noeman Received Received
  FRI-321 Development of a district general hospital liver nurse service for patients with acute and chronic liver conditions Amy Thatcher Received Received
  FRI-322 Managing decompensated cirrhosis - the importance of multidisciplinary engagement Dev Katarey Received Received
  THU-322 Screening of components involved in activation of innate immune responses and inflammation in NEMO KO mice Mick Frissen Received Received
  SAT-324 Suboptimal linkage to care after identification of serum hepatitis B surface antigen-positive individuals in territory-wide screening: a need for educational and public health policies Kwan Lung Ko Received Received
  FRI-324 Prospective study of therapeutic education (TE) designed with a multidisciplinary team and participation of patients to improve the adherence to treatment of the patients and their quality of life (QOL) Dominique Larrey Received Received
  THU-325 Bioengineering of 3D bile ducts from 2D micropatterns by self-organogenesis Pascale Dupuis-Williams Received Received
  SAT-326 Microelimination of chronic hepatitis C in Romania - another pathway to achieve national elimination goals by HepC ALERT project Speranta Iacob Received Received
  THU-327 Analysis of HBV full-genome haplotypes from immune tolerant-, immune clearance-, and immune resolution phase of chronic hepatitis B virus disease Josef Wagner Received Received
  THU-328 Tolerogenic dendritic cells modulate pathogenic CD4 T cells in an ex vivo co-culture system in a concanavalin A -mice model of type-I autoimmune hepatitis Prabhsimran Singh Received Received
  FRI-329 Diet lifestyle management of non-alcoholic fatty liver disease (NAFLD): a cross-sectional survey of clinicians Laura Haigh Received Received
  SAT-329 Incidence of HCV infection among gbMSM in British Columbia, Canada: a population-based cohort study James Wilton Received Received
  FRI-330 Development of clinical professional standards for liver transplant nursing Michelle Clayton Received Received
  SAT-330 An OST (opiate substitution therapy)-based hepatology service facility (OHSF) with access to chronic hepatitis C treatment: the example of an one stop shop as a practical step towards HCV elimination in patients who use drugs (PWUD) Nikolaos Papadopoulos Received Received
  THU-331 Phenotypic characterization of ABCG5/G8 deficiency: ive knockout in liver or intestine leads to genocopies Susanne N Weber Received Received
  FRI-332 Prospective evaluation of a non-alcoholic fatty liver disease assessment pathway; impact of clinical nurse specialist role Marie McGrath Received Received
  SAT-333 Development of a supportive needs assessment tool for cirrhosis (SNAC) Patricia Valery Received Received
  THU-333 Upregulation of CCNB1, CDC20 and CENPF genes is associated with poor prognosis in hepatocellular carcinoma (HCC) Tengfei Si Received Received
  THU-334 Bax inhibitor-1 inhibits acetaminophen induced hepatotoxicity by reducing the drug induced ER stress through regulating the RIDD activity of IRE1 alpha Thoufiqul Alam Riaz Received Received
  SAT-334 Inequities in presentation and outcomes for indigenous Australians hospitalised for cirrhosis Patricia Valery Received Received
  SAT-336 Catalytic funding of viral hepatitis elimination program in Uzbekistan Rick Dunn Received Received
  THU-338 Investigating the mechanism of treating acute-on-chronic liver failure with human bone marrow-derived mesenchymal stem cells via hepatocytes exosomal miRNAs ZHANG JING Received Received
  FRI-338 Plasmacytoid dendrtic cells protect against acute liver injury via IL-35 Yuzo Koda Received Received
  SAT-339 Updated estimate for prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin Robert Wong Received Received
  THU-341 Kidney transplant from hepatitis C positive donors to hepatitis C negative recipients: report on the first experience in the UK Brendan Healy Received Received
  THU-342 Pharmacy-based molecular point-of-care testing for hepatitis C (HCV) in high-risk patients: feasibility and linkage to care Benedict Rogers Received Received
  SAT-342 High patient acceptability for a hepatitis C mobile outreach service targeting vulnerable homeless communities - an important component for elimination? Sarah Montague Received Received
  THU-344 Screening and treatment difficulties of hepatitis C virus infected patients with substance use disorders or dual pathology, despite centralized management in an addiction and dual diagnosis center Cristina Marcos Fosch Received Received
  FRI-344 Drug screening against complement disorders using human stem cell-derived endothelium and liver organoids Yasunori Nio Received Received
  THU-345 Integrating hepatitis C virus screening by dry blood spot test into colorectal cancer screening: a randomized controlled trial María Cristina Reygosa Castro Received Received
  SAT-345 National survey among people who use drugs (PWUD) on opioid substitution treatment (OST) on their knowledge of hepatitis C virus (HCV) infection and barriers for treatment in Bulgaria Marieta Simonova Received Received
  THU-346 Ethnic disparities in the risk of hepatitis C virus-related diabetes in a large population-based cohort in Canada Dahn Jeong Received Received
  SAT-347 Barking up the wrong tree: why universal hepatitis C virus screening is not enough for its elimination in the US Pimsiri Sripongpun Received Received
  FRI-347 Platelet activation during chronic hepatitis B infection exacerbates liver inflammation and promotes fibrosis Qirong Jiang Received Received
  THU-348 Telemedicine and decentralized treatment dispensation to rescue patients in a hepatitis C micro-elimination program based on on-site dried blood spot testing in drug addiction centers Dalia Morales Arraez Received Received
  THU-349 The success of outreach hepatitis C screening among a Belgian population of drug users in a rural and urban setting Dana Busschots Received Received
  FRI-350 Potential biomarkers of response in chronic hepatitis B patients who achieved HBeAg loss upon treatment with toll-like receptor 8 (TLR8) agonist selgantolimod Diana Chen Received Received
  SAT-351 Factors associated with failure to link people who inject drugs to HCV care and treatment: results from a community-based seek-test-treat program in Athens, Greece (ARISTOTLE HCV-HIV) Vana Sypsa Received Received
  SAT-352 Clinical and economic consequences of antiviral treatment for hepatitis C chronic infection in Europe: analysis of England, Italy, Romania and Spain data Loreta A. Kondili Received Received
  FRI-352 Extracellular HBsAg clearance has minimal impact on CD8 T cell responses in mouse models of HBV pathogenesis Valeria Fumagalli Received Received
  THU-353 The HSD17B13 rs6834314 variant is associated with liver stiffness measurement in untreated HCV-3 patients with cirrhosis Enrico Galmozzi Received Received
  FRI-355 Hepatitis B virus kinetics after nucleos(t)ide-analogue withdrawal in chronic HBeAg(-) hepatitis correlates with HBV-specific CD8 response and HBsAg level Julia Peña Asensio Received Received
  THU-355 Hepatitis C reflex testing in Spain in 2019: a story of success Federico Garcia Received Received
  THU-356 Cracks in the hepatitis C cascade of care: real-life outreach data from four Central London services Hui Mei Wong Received Received
  SAT-356 Hormone replacement therapy is associated with reduced liver cirrhosis risk and improved survival in treatment-naive hepatitis B- and/or C- infected postmenopausal women: a nationwide long-term population-based cohort study Yuan-Tsung Tseng Received Received
  THU-357 Seroprevalence of hepatitis B virus co-infection among HCV infected patients screened during the national campaign for HCV eradication in Egypt Hadeel Gamal Eldeen Received Received
  FRI-357 Hepatitis B virus-specific CXCR5 CD8 T cells may be related to hepatitis B virus clearance in chronic hepatitis B patients treated with pegylated interferon alpha Li Zhang Received Received
  SAT-357 Hepatitis B virus core protein variants observed in a first-in-human placebo-controlled study of a core protein inhibitor Emily P. Thi Received Received
  FRI-358 Hepatitis B virus-specific CXCR5 CD8 T cells shows stronger functional activity in a mouse model of acute hepatitis B virus infection Li Zhang Received Received
  THU-358 Risk of liver and non-liver-related mortality among hepatitis C virus and human immunodeficiency virus co-infected persons in a cohort of Brazilian blood donors: a twenty-year study Helio Ranes Filho Received Received
  SAT-359 Establishment of human induced pluripotent stem cell-derived hepatocyte-like cells permissive for serum-originated hepatitis B virus infection and allowing for covalently closed circular DNA inhibitor drug screening Chau-Ting Yeh Received Received
  THU-359 Emergency department screening for hepatitis C carriers does not improve linkage to care - a single-center prospective study Inbal Houri Received Received
  FRI-361 Peripheral soluble protein, transcriptomic, and methylation biomarkers associated with HBsAg loss in patients with chronic hepatitis B Diana Chen Received Received
  SAT-361 Analysis of hepatitis B virus quasispecies in circulating viral DNA and RNA: are genotype and complexity different? David Tabernero Received Received
  SAT-362 Mitochondrial DNA damage and mitochondrial dysfunction in patients with chronic hepatitis B Dimitri Loureiro Received Received
  FRI-362 Tox expression on HBV-specific CD8 T cells is linked to clinical stage of chronic HBV infection Kathrin Heim Received Received
  FRI-364 Distinct serum HBsAg levels show minimal effect on gene expression profiles of blood leukocyte subpopulations in non-viremic chronic HBV patients. Noe Axel Rico Montanari Received Received
  SAT-365 Characterization of acute hepatitis C virus infection and transmission clusters by next-generation sequencing among people who inject drugs in Catalonia Elisa Martró Received Received
  THU-365 Global timing of hepatitis C virus elimination in high-income countries: an updated analysis Yuri Sanchez Gonzalez Received Received
  THU-366 Anticipated timing of elimination of hepatitis C virus in Canadas four most populous provinces Yuri Sanchez Gonzalez Received Received
  FRI-367 Profiles of expression of costimulatory molecules OX40 and OX40l in PBMCs and levels of soluble OX40/OX40l in plasma in chronic hepatitis B patients and health subjects Mengru Zhan Received Received
  THU-367 Acute hepatitis C virus infection: a prospective ten-year observational study of HCV-mono and HCV/HIV-coinfected patients Julia Dietz Received Received
  FRI-368 Phenotypic variation among myeloid-derived suppressor cells (MDSC) in natural history phases of chronic HBV infection differentially impacts HBV-specific T cell response and homing: lack of functional normalization after anti-viral therapy Sourina Pal Received Received
  SAT-368 Usefulness of dried plasma spots using a plasma separation card for serological diagnosis of chronic hepatitis B and C and reflex viral load testing Joan Martinez Received Received
  SAT-369 Validity of a point-of-care viral load kit for hepatitis B in a low-income setting Corina Rueegg Received Received
  FRI-370 Higher proportion of responders with hepatitis B antibody levels =100 miu/ml with the trivalent HepB vaccine, Sci-B-Vac, compared to Engerix-B: results from the phase 3 double-blind, randomized study comparing immunogenicity and safety (PROTECT) Timo Vesikari Received Received
  THU-371 Micro-elimination of hepatitis C in mental health care settings Kristen McKee Received Received
  THU-372 Triple E (engagement, education and eradication) for patients with chronic hepatitis C infection: 2 years of results of a successful, collaborative US model for improving education, screening and linkage to care in an underserved population Jane Ranagan Received Received
  FRI-373 Serum levels of circulating DNA species can predict the development of hepatocellular carcinoma in chronic hepatitis B patients under long-term oral antiviral therapy George Papatheodoridis Received Received
  SAT-373 From in vivo to in vitro: ex vivo studies using primary human hepatocytes from chronically diseased liver-humanized FRG KO mice LANDER FOQUET Received Received
  THU-373 Prevalence of hepatitis C in a gastrointestinal endoscopy unit. An active search for asymptomatic subjects Laura Gomez-Escolar Viejo Received Received
  SAT-374 The head-start project Georgia: a three-armed, cluster, non-randomised trial of the effectiveness of two novel models of HCV confirmatory testing in harm reduction sites (HRS) in Georgia Maia Japaridze Received Received
  FRI-374 Immunological and virological markers during pegylated interferon therapy in HDV chronic hepatitis: any predictor of response? Antonella Olivero Received Received
  SAT-375 HBeAg seroconversion during treatment with peginterferon-alfa2a (PEG-IFN) is preceded by ion of hepatitis B virus basal core promoter and pre-core variants which are associated with decreased HBV replication Maria Pfefferkorn Received Received
  THU-375 Timing of hepatitis C elimination in the United States: estimating the year each state will meet the World Health Organizations elimination targets Carrie Bray Received Received
  SAT-376 Targeting hepatitis B virus with CRISPR/Cas9 approach Barbara Testoni Received Received
  FRI-376 Is it possible to stop nucleus(t)die analogue safely in patients with preemptive or preventive therapy for HBV reactivation? Akihiro Tamori Received Received
  THU-376 Managing hepatitis C in people who inject drugs (PWID) using the internist-addiction medicine-hepatology (IAHC) model to achieve Hep C micro-elimination Naren Srinath Nallapeta Received Received
  THU-377 Testing and treatment for hepatitis C in the community pharmacy setting: an opportunity not to be missed? Nicki Palmer Received Received
  SAT-378 The correlations between HBV markers and HBV cccDNA in the patients during Na treatment Takeshi Matsui Received Received
  THU-378 Hepatitis C virus antigen detection as a tool for diagnosis of acute hepatitis C in patients with negative hepatitis C virus antibody Rajneesh Kumar Received Received
  FRI-378 Evolution of care quality metrics for chronic hepatitis B in the hepatitis C direct-acting antiviral era David Kaplan Received Received
  SAT-380 Prospective study of hepatitis B virus infection and its genotypes in the north-eastern India region Premashis Kar Received Received
  FRI-381 Evaluation of dried plasma spot on the cobas(r) plasma separation card as a sample type for hepatitis B virus load quantification on the cobas(r) 6800 system Ariadna Rando Segura Received Received
  THU-381 Missed linkage to care for patients with chronic hepatitis C virus infection in a tertiary care center: results of the telepass project Francesco Santopaolo Received Received
  FRI-382 Genetic variants do not predict the development of hepatocellular carcinoma in cross-sectional and longitudinal studies including caucasian compensated HBV cirrhotics treated with NUC for 10 years Enrico Galmozzi Received Received
  SAT-383 Cryptic HBV viremia in anti-HBC positive/HBsAg negative patients with HIV infection is frequently revealed by applying an ultrasensitive droplet digital PCR assay Romina Salpini Received Received
  FRI-383 PAGE-B score is simpler and has similar predictive performance with the new Asian hepatocellular carcinoma risk scores in Caucasian chronic hepatitis B patients treated with long-term entecavir or tenofovir disoproxil fumarate therapy George Papatheodoridis Received Received
  THU-384 Direct-acting antivirals have substantially modified the profile of patients with cirrhosis who require hospitalization in Spain Sergio Rodriguez Tajes Received Received
  FRI-384 Hepatitis B core-related antigen and viral loads status impacts on the risk of hepatocellular carcinoma in patients with HBeAg-negative chronic hepatitis B virus infection Tetsuya Hosaka Received Received
  SAT-384 Osteopontin drives HBV replication and HBV-driven fibrogenesis and represents a novel therapeutic target to achieve functional cure in chronic hepatitis B Sandra Phillips Received Received
  SAT-386 Viral compartmentalization and carcinogenesis at single-cell level in HBV-induced hepatocellular carcinoma Antonio Saviano Received Received
  THU-386 Patients with hepatitis C (Redpath): a randomised controlled trial of telephone contact or offer of an incentive, in addition to a standard letter stephen barclay Received Received
  THU-387 Overdose events among active drug users successfully treated for HCV: the impact of homelessness Tianna Magel Received Received
  FRI-387 Gender disparity in the association of interleukin-10 and interleukin-12 polymorphisms with the progression of hepatitis B virus infection in Caucasians Janett Fischer Received Received
  SAT-387 Pangenotypic therapies glecaprevir-pibrentasvir (G-P) and sofosbuvir-velpatasvir-voxilaprevir (S-V-V) after failure with interferon (IFN)-free direct-acting antiviral (DAA) treatment for hepatitis C Steven Flamm Received Received
  SAT-388 A novel intrahepatic restriction factor, HMGA1, contributes to hepatitis B virus (HBV) replication in immune tolerant phase, serving as an anti-HBV target Jingwen Wu Received Received
  FRI-389 Risk of hepatitis flare in inflammatory bowel disease patients with previous hepatitis B virus exposure - results from a territory-wide Hong Kong ibd registry study Joyce Wing Yan Mak Received Received
  THU-390 Epidemiological evolution of viral hepatitis in uremic patients in Taiwan - the Formosa like group Yu-Ju Wei Received Received
  SAT-390 Evaluation of the introduction of hepatitis C core antigen as a routine test to detect viraemia among patients with anti-HCV antibodies stephen barclay Received Received
  FRI-390 Sarcopenia is associated with type 2 diabetes and sedentary lifestyle in patients with chronic hepatitis B Luciana Diniz Silva Received Received
  SAT-391 Virologic causes for DAA treatment failure of chronic hepatitis C Chun-Jen Liu Received Received
  FRI-392 Incidence and predictors of hepatitis B surface antigen clearance among people living with HIV and hepatitis B Mamta Jain Received Received
  SAT-393 Usefulness of HEV antigen determination in the diagnosis of acute hepatitis E Víctor Jiménez Beltrán Received Received
  FRI-393 Rituximab monotherapy in anti-HBC positive patients with multiple sclerosis or neuromyelitis optica spectrum disorders is not associated with HBV reactivation Mar Riveiro Barciela Received Received
  THU-393 Improvement of all HCV care cascade steps in IVDU treated with DAAs within a dedicated program Alessandra Mangia Received Received
  THU-395 Concomitant use of direct-acting antivirals (DDAs) and central nervous system drugs in current chronic hepatitis C patient profile Maria Sainz Received Received
  FRI-395 Poor improvement of on-treatment FIB-4 index after initiation of nucleos(t)ide analogs is associated with development of hepatocellular carcinoma in both cirrhotic and non-cirrhotic chronic hepatitis B patients Miyako Murakawa Received Received
  SAT-395 Resistance monitoring data from treatment-naive chronic HBV infected patients treated for 28 days with a new class a core protein allosteric modulator RO7049389 monotherapy Xue Zhou Received Received
  THU-396 Glecaprevir/pibrentasvir for the treatment of hepatitis C virus infection among active drug users: the grand plan study Brian Conway Received Received
  FRI-396 The integrated use of accurate virological and serological HBV markers can help identifying HBsAg-negative/anti-HBC -positive patients at higher risk of HBV-reactivation and optimizing the duration of prophylaxis in oncohematological setting Mohammad Alkhatib Received Received
  THU-397 Direct-acting antiviral treatment in patients infected with a non-epidemic hepatitis C genotype in the Netherlands: results from a nationwide cohort study Cas Isfordink Received Received
  FRI-399 Early detection of chronic hepatitis B and risk factor assessment in Turkish migrants, Middle Limburg, Belgium zgr Koc Received Received
  THU-399 Alcohol use does not influence treatment uptake or outcomes in the DAA era David Mackie Received Received
  THU-400 Influence of baseline resistance on treatment outcome in patients treated for chronic hepatitis C in Denmark: a nationwide study christina slund Received Received
  SAT-400 Effectiveness of hepatitis A vaccination in human immunodeficiency virus-infected men who have sex with men during an outbreak of hepatitis A in Osaka, Japan Hiroki Bessho Received Received
  FRI-401 Impact if HBV infection in HCV/HBV coinfected patients treated with DAAs in north Italy Paolo Fabris Received Received
  THU-401 Inadvertent off label DAA treatment in the real-world and importance for virologic outcome - data from the German hepatitis C-Registry (DHC-R) Yvonne Serfert Received Received
  SAT-402 Epidemiology of fulminant hepatitis A cases in Vienna - an informative case series David JM Bauer Received Received
  FRI-402 Quantitative HBeAg varies in the different phases of HBV infection, and can predict therapeutic outcome in the setting of immunosuppression driven HBV reactivation Lorenzo Piermatteo Received Received
  FRI-403 Development of a highly sensitive multiplex platform assay to monitor low levels of HBV DNA and pgRNA in samples from patients with chronic hepatitis B Lisa Danzig Received Received
  SAT-403 Epidemiology of fulminant hepatitis E cases in Vienna - an informative case series David JM Bauer Received Received
  THU-404 Grazoprevir/elbasvir for treatment of hepatitis C virus genotype 4 post kidney transplant Faisal Abaalkhail Received Received
  FRI-404 Very low rates of receiving antiviral therapy among treatment eligible chronic hepatitis B virus infected patients Robert Wong Received Received
  SAT-405 Are we aligned with WHO international strategy to eliminate hepatitis C by 2030: real-world data from Khyber Pakhtunkhwa, Pakistan Bakht Biland Received Received
  FRI-405 Impact of hepatitis B virus-related immune reconstitution inflammatory syndrome on HBsAg loss in patients co-infected with human immunodeficiency virus Sachiyo Yoshio Received Received
  FRI-406 Response to a double dose (40 mcg) and an accelerated schedule (0-1-2 months) of hepatitis B vaccine in patients with advance cirrhosis. A prospective study Sergio Rodriguez Tajes Received Received
  SAT-406 Hepatitis E seroprevalence and rate of viremia in immunocompromised patients - a systematic review and meta-analysis Gustav Buescher Received Received
  THU-406 Integrated efficacy and safety analysis of GT1-6 treatment-naive, non-cirrhotic and compensated cirrhotic patients who received 8 weeks of glecaprevir/pibrentasvir Jeff Lehman Received Received
  SAT-407 Therapeutic window for ribavirin therapy in transplant recipients with chronic hepatitis E virus infection Midas Mulder Received Received
  THU-407 Hepatitis C micro-elimination pilot strategy in Pakistani migrants in Catalonia through the implementation of a community intervention: interim results of the HepC-link study Elisa Martró Received Received
  FRI-407 Presence of significant histopathology in HBeAg-positive chronic infection patients identified by four international guidelines: a Chinese multi-center study Yidi Jia Received Received
  SAT-409 Hepatitis E virus genotype 3 subtype dependent clinical outcomes in Belgium 2010-2018 Michael Peeters Received Received
  THU-410 The outcome of re-treatment of relapsed hepatitis C virus infection after direct acting antiviral treatment failure in resource-limited settings Gina Naguib Received Received
  FRI-410 Evaluation of page-b and modified page-b scores to guide hepatocellular carcinoma surveillance in chronic hepatitis B patients on antiviral therapy - a territory-wide study of 32,150 subjects Terry Cheuk-Fung Yip Received Received
  SAT-410 Hepatitis E virus infection in liver transplant recipients in Sweden Miriam Karlsson Received Received
  SAT-411 Hepatitis E virus shedding in semen of chronically, but not acute HEV infected individuals Thomas Horvatits Received Received
  THU-412 A phase 2, open-label study of pan-genotype regimen of SH229 plus daclatasvir in Chinese patients with chronic hepatitis C virus infection Xian Zhang Received Received
  THU-413 Health-related quality of life (HRQOL) before and after treatment of genotype 1 (GT1) infection with elbasvir/grazoprevir (EBR/GZR): results from the German hepatitis C registry (DHC-R) Markus Becker-Camps Received Received
  FRI-414 Clonal expansion of hepatocytes and state of hepatitis B virus DNA integration in patients with nucleos(t)ide analogue therapy Ning CHOW Received Received
  SAT-414 Efficacy and safety of treatment interruption in patients with HBeAg negative chronic hepatitis B Teresa Broquetas Received Received
  THU-415 Use of sofosbuvir based direct acting antiviral regimens is associated with reduced mortality in liver transplant candidates with hepatitis C Ajay Israni Received Received
  SAT-415 Pegylated interferon beta strongly reduces all serological and intrahepatic hepatitis B virus parameters in immunodeficient humanized mice Andrea Pirosu Received Received
  SAT-416 hzVSF, a novel HBV therapeutic candidate, shows WHsAg loss in woodchuck hepatitis model and safety in phase I clinical study Byoung Ahn Received Received
  FRI-416 Cessation of nucleos(t)ide analogues therapy in chronic hepatitis B: a systematic review and meta-analysis Yandi Xie Received Received
  THU-416 Factors associated with efficacy of retreatment with grecaprevir/pibrentasvir therapy in prior DAA failed patients - nationwide multicenter study in Japan Jun Itakura Received Received
  SAT-417 Safety and efficacy of up to 76 weeks 10mg (high dose) bulevirtide monotherapy in compensated cirrhotics with delta hepatitis Alessandro Loglio Received Received
  THU-417 Impact of the universal access to direct-acting antivirals in the profile of hepatitis C treated patients Jordi Llaneras Received Received
  FRI-418 Estimating the clinical and economic burden of chronic hepatitis B (CHB) in the United States Carey Escheik Received Received
  THU-418 Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease - data from the German hepatitis C-registry (DHC-R) Yvonne Serfert Received Received
  SAT-419 The establishment of hepatitis B care and treatment clinics with viral load testing capacity in the United Republic of Tanzania: a demonstration project following WHO guidelines, Zanzibar, 2017-2019 Ali Salum Received Received
  THU-419 HCV in the Australian primary care setting: real-world effectiveness of 12 weeks of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C Joss OLoan Received Received
  SAT-420 Nucleos(t)ide analogue therapy decreases the HBeAg loss rate in HBeAg positive chronic hepatitis B patients with hepatitis flare: a propensity score matching study Chien-Wei Peng Received Received
  FRI-420 Risk of hepatocellular carcinoma recurrence in patients treated with direct acting antiviral therapy Asmaa Gomaa Received Received
  FRI-421 Evidence of declining HCV transmission in Australia following scale-up of direct acting antiviral therapy Gregory Dore Received Received
  FRI-422 HIV co-infection is associated with lower risk of liver cancer after HCV-cure ANAIS CORMA-GOMEZ Received Received
  THU-422 The English hepatitis C registry shows only a modest effect from non-completion of directly-acting antivirals for hepatitis C: SVR rates over 80 in genotype 1, 2 or 3 HCV if more than one third of planned treatment is completed Kate Drysdale Received Received
  SAT-422 ATI-2173, a novel phosphoramidate nucleoside prodrug for HBV cure regimens Douglas Mayers Received Received
  THU-423 Evolution of hepatitis C virus genotype 1a vs 1b distribution reflects profound changes in HCV epidemiology in Germany - analysis of 17,093 patients from five consecutive registries including the German hepatitis C-registry (DHC-R) Yvonne Serfert Received Received
  SAT-423 The role of HBV genotypes in HBV relapse after cessation of entecavir or tenofovir in HBeAg-negative patients without cirrhosis Chien-Hung Chen Received Received
  FRI-424 Medium-term outcomes of hepatitis C virus-infected patients with a sustained viral response according to albumin-bilirubin grade Akihiro Tamori Received Received
  THU-424 The quetiapine question: management strategies for drug-drug interactions with antipsychotics and direct acting antivirals; a multicentre review Katherine Davidson Received Received
  SAT-424 Impact of ESC technology on the hepatic safety profile of GalNAc-delivered, HBV-targeting RNAi therapeutics Daniel Cloutier Received Received
  FRI-425 Identification of serum miRNAs whose expression were associated with and changed after HCV eradication Atsumasa Komori Received Received
  SAT-425 A once-per-week or every-two-week dosing regimen is more efficacious for the TIR7 agonist JNJ-64794964 (JNJ-4964) to induce an anti-hepatitis B virus (HBV) effect and HBV-specific immune responses in AAV-HBV mice Florence Herschke Received Received
  THU-425 Identification of patients with compensated cirrhosis who can safely use protease inhibitor-based therapy for HCV infection Lisette Krassenburg Received Received
  SAT-426 In vitro and in vivo characterization of VIR-2218, an investigational RNAi therapeutic targeting hepatitis B virus Florian Lempp Received Received
  FRI-426 Impact of genetic variants on liver disease regression in HCV patients with advanced chronic liver disease who achieved SVR to IFN-free therapies Bernhard Scheiner Received Received
  SAT-427 Real-world experience from tenofovir alafenamide use in chronic hepatitis B: an Hellenic multicenter real-life clinical study (HERACLIS-TAF) George Papatheodoridis Received Received
  THU-427 Global real-world evidence of sofosbuvir/velpatasvir (SOF/VEL) as a highly effective treatment and elimination tool in underserved patient populations experiencing mental health disorders, incarceration or homelessness Candido Hernandez Received Received
  SAT-428 Early PEG-interferon-related ALT flares of high magnitude lead to HBsAg decline and loss. A study of 639 chronic hepatitis B patients Hannah S.J. Choi Received Received
  FRI-428 HIV/HCV co-infected subjects show better thrombocytopenia improvement after sustained virologic response achievement than HCV mono-infected cirrhotics. Data from the hepaiCONA and PITER cohorts. Roberto Rossotti Received Received
  THU-428 Innovative procedures for micro-elimination of HCV infection in a high-risk population of undocumented migrants and low-income refugees Lorebzo Onorato Received Received
  THU-429 Elimination of hepatitis C in a remand prison using a rapid point of care driven test and treat pathway Louise Davies Received Received
  THU-430 Dermatological manifestations in the era of new direct acting antivirals: a single-center experience Mohamed Talkhan Received Received
  SAT-430 Residual low HDV viremia is associated with HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis D (delta): results from the HIDIT-II study Heiner Wedemeyer Received Received
  FRI-430 Development of hepatocellular carcinoma by patients aged 75 years or over after HCV elimination by all-oral DAA therapy: results from a large-scale, multicenter cohort study Eiichi Ogawa Received Received
  FRI-431 Deteriorated lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication Chung-Feng Huang Received Received
  SAT-431 Combination drug interactions of hepatitis B virus (HBV) S-antigen transport - inhibiting oligonucleotide polymers in vitro Hua Tan Received Received
  THU-432 Real-life experience of direct acting antiviral treatment for chronic hepatitis C infection in adolescent patients in a low prevalence setting Mary Flanagan Received Received
  FRI-432 Dynamic of cytokine profiles predicts risk of HCC among HCV patients with advanced fibrosis after successful antiviral therapy Ming-Lung Yu Received Received
  SAT-433 Early on-treatment ALT normalization in patients with chronic hepatitis B is associated with lower risk of hepatocelluar carcinoma development Jong Eun Yeon Received Received
  FRI-433 Procoagulant imbalance in patients with non-cirrhotic chronic hepatitis C (CHC) improves six months after eradication with direct-acting antiviral agents (DAAs) and likely correlates with liver fibrosis Giordano Sigon Received Received
  SAT-434 Best in class hepatitis B virus anti-sense oligonucleotides: next generation bridged nucleic acid chemistries significantly improve the therapeutic index by reducing hepatotoxicity and increasing in vivo efficacy in a mouse model Jin Hong Received Received
  THU-435 Drug-drug interactions (DDIs) with pangenotypic direct-acting antivirals (DAAs) in patients with hepatitis C; understanding the populations at risk and real-world care management Michael Curry Received Received
  THU-436 Patient-reported outcomes among people receiving opioid agonist therapy and treatment for hepatitis C virus infection: results from CO-STAR Michael Winterrowd Received Received
  THU-437 Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir as a hepatitis C virus infection salvage treatment James Wilton Received Received
  THU-438 A combination of AT-527, a pan-genotypic guanosine nucleotide prodrug, and daclatasvir was well-tolerated and effective in HCV-infected subjects Xiao-Jian Zhou Received Received
  SAT-438 Solving the cold chain problem - development of a heat-stable therapeutic vaccine to combat chronic hepatitis B Julia Sacherl Received Received
  THU-439 Frequency and characteristics of DAAs failure in hepatitis C therapy Pablo Florez-Díez Received Received
  SAT-439 Multicistronic DNA-based therapeutic vaccine as a promising candidate to treat chronic hepatitis B virus (HBV) infection Helene Kerth Received Received
  FRI-440 Simple blood test criteria for non-cirrhosis plus age and post-treatment AFP rule-out the risk of hepatocellular carcinoma development after SVR Masayuki Kurosaki Received Received
  SAT-440 EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor: Final Results of a Phase 1 Study in Healthy Adult Subjects Kajal Larson Received Received
  THU-440 Real-world clinical practice outcomes in hepatitis C-infected patients with psychiatric and substance use disorders treated with glecaprevir/pibrentasvir for 8 or 12 weeks: a pooled analysis across nine countries Jeff Lehman Received Received
  FRI-441 Risk of end-stage renal disease among hepatitis C patients with chronic kidney disease treated with and without sofosbuvir Laura Telep Received Received
  THU-441 Fast-track-consultation protocol: an interdisciplinary and useful tool for treating drug user hepatitis C infection in addiction out-patient units Silvia Acosta-López Received Received
  FRI-442 The weight of pre-existing cofactors for liver disease progression in patients who successfully eradicated chronic hepatitis C viral infection: an interim analysis in the PITER cohort Loreta A. Kondili Received Received
  THU-442 Achieving hepatitis C elimination in people who inject drugs - interim results of an innovative screen-and-treat program in Austria Caroline Schmidbauer Received Received
  THU-443 Directly observed therapy for hepatitis C with sofosbuvir/velpatasvir alongside opioid substitution as a tailored microelimination strategy in PWIDs with a high risk of non-adherence - real-world data from Vienna, Austria Caroline Schmidbauer Received Received
  FRI-443 Clinical impact of direct-acting antiviral treatment on patients affected by hepatitis C virus-related oral lichen planus Marco Di Petrillo Received Received
  THU-444 Externalized HCV linkage-to-care cascade in the biggest harm reduction center in Barcelona: approaching a high-risk PWID population Sabela Lens Received Received
  SAT-444 Low HBcrAg and HBsAg levels identify patients most likely to achieve sustained response after nucleos(t)ide analogue cessation: results from a global individual patient data meta-analysis (create study ) Milan Sonneveld Received Received
  SAT-445 Silencing HBV expression using LNA gapmers: preliminary data of a new promising strategy Maria Francesca Cortese Received Received
  SAT-446 The composition of HBsAg during peginterferon-alfa2a treatment can predict treatment response in HBV/HDV-coinfection Maria Pfefferkorn Received Received
  SAT-447 All-cause mortality and liver-related death following entecavir, tenofovir disoproxil fumarate or lamivudine therapy among treatment-naive chronic hepatitis B patients in British Columbia, Canada Mawuena Binka Received Received
  FRI-447 The one-year outcome of hepatitis B virus in Taiwanese patients with chronic hepatitis B and C co-infection after direct-acting antivirals Ming-Lun Yeh Received Received
  THU-447 Microelimination beyond prison walls: subjects sentenced to non-custodial sentences, screening and immediate assisted treatment with navigator figure and telemedicine Susana Llerena Received Received
  SAT-448 Differential tenofovir alafenamide (TAF) adoption in HBV-infected populations; assessment of care in US clinical practice Michael Curry Received Received
  THU-448 Efficacy of sofosbuvir/velpatasvir (s/v): impact of treatment adherence Tianna Magel Received Received
  FRI-448 Hepatitis C reinfection by treatment pathway among people who inject drugs in Tayside, Scotland Madeleine Caven Received Received
  FRI-450 Influence of DAA treatment in patients with HCV-cirrhosis and esophageal varices on liver transplant free survival and risk of developing hepatocellular carcinoma Noelia Rodríguez Ferreiro Received Received
  SAT-451 Efficacy and safety of switching to tenofovir alafenamide for chronic hepatitis B patients with advanced fibrosis and partial virologic response to oral nucleos(t)ide analogues (ESTAB-AFPVR) - an interim report Ming-Lun Yeh Received Received
  THU-451 HCV DAA treatment failure is associated to hepatocellular carcinioma presence Ubaldo Visco-Comandini Received Received
  SAT-452 Efficacy and safety of GLS4/ritonavir combined with entecavir in HBeAg-positive patients with chronic hepatitis B: interim results from phase 2b, multi-center study Mingyuan Zhang Received Received
  FRI-453 Hepatocellular carcinoma following direct acting antiviral therapy does not display an aggressive pattern: a prospective study Reham Soliman Received Received
  FRI-454 Long-term evaluation of liver stiffness in HCV patients after sustained virological response to DAAs: predictive factors for disease improvement and hepatocellular carcinoma development Riccardo Nevola Received Received
  THU-455 Hepatitis C positive organ transplantation to negative recipients at a multi-organ Canadian transplant centre: ready for prime time Waleed Alghamdi Received Received
  FRI-455 Hepatitis C virus infection, endogenous retrotransposons activation and cancer risk Ruchi Shukla Received Received
  FRI-456 Post-treatment wisteria floribunda agglutinin-positive mac-2-binding protein is a useful predictor of hepatocellular carcinoma development after hepatitis C virus eradication Shunsuke Sato Received Received
  FRI-457 Erradication of HCV with direct-acting antivirals increased small LDL particle number in SVR48 Vanesa Bernal Monterde Received Received
  SAT-457 Longer-term experience with tenofovir alafenamide (TAF) in HBV-infected patients; changes in EGFR, FIB4, ALT, and DNA suppression Rajender Reddy Received Received
  THU-458 Neutrophil-lymphocyte ratio predicts the risk of developing hepatocellular carcinoma in cirrhotic patients with chronic hepatitis B under antiviral therapy Ke Shi Received Received
  SAT-458 Immtav, a novel immunotherapy approach to eliminate hepatitis B virus Ruth Martinez Hague Received Received
  THU-459 Differentiation and management of hepatobiliary mucinous cystic neoplasms: a single-center experience for 10 years Junhao Zheng Received Received
  SAT-459 HBV RNA decline without concomitant HBsAg decrease is associated with a low probability of sustained response and HBsAg loss Sylvia Brakenhoff Received Received
  FRI-459 Partial restoration of brain structural and connectivity changes after HCV cure with direct acting antivirals (DAA) Zoe Mariño Received Received
  SAT-460 HBV specific ImmTAV induce a broad immune response enabling the elimination of HBV positive cells Joannah Fergusson Received Received
  THU-460 Prognostic significance of systemic immune-inflammation index in patients with intrahepatic cholangiocarcinoma undergoing hepatic resection Hui Li Received Received
  THU-461 Serum and urine extracellular vesicles contain specific RNAs with diagnostic capacity for cholangiocarcinoma, being possibly involved in disease pathogenesis Ainhoa Lapitz Received Received
  THU-462 Novel protein biomarkers in serum extracellular vesicles for the diagnosis of cholangiocarcinoma (CCA) in patients with primary sclerosing cholangitis (PSC) Ainhoa Lapitz Received Received
  SAT-462 Pharmacokinetics of VIR-2218, an RNAi therapeutic for the treatment of HBV infection, in healthy volunteers Sneha V. Gupta Received Received
  SAT-463 Characterization of IL-21-expressing recombinant hepatitis B virus (HBV) as a therapeutic agent targeting persisting HBV infection Jingwen Wu Received Received
  FRI-463 NK-cell dysfunction in hepatocellular carcinoma: modulatory approches for functional restoration Alessandra Zecca Received Received
  SAT-466 Functional cure based on pegylated interferon ? in long-term nucleoside analog suppressed HBeAg negative chronic hepatitis B: a multicenter real-world study (Everest project in China), an interim report Ze-Qian Wu Received Received
  SAT-467 Occurence of hepatocellular carcinoma in chronic hepatitis B patients undergoing entecavir or tenofovir treatment: a multicenter study in Taiwan Yi-Hsiang Huang Received Received
  THU-467 Serum cytokeratin-19 fragments (CYFRA 21-1) for the prediction of overall survival in patients with hepatocellular carcinoma Gian Paolo Caviglia Received Received
  THU-468 Contrast-enhanced ultrasound using sonazoid in liver imaging reporting and data system category 3 and 4 observations on gadoxetate-enhanced magnetic resonance imaging Yeun-Yoon Kim Received Received
  SAT-468 Anti-HBS induction and HBsAg reduction by nasal administration of a therapeutic vaccine containing HBsAg and HBcAg (NASVAC) in patients with chronic HBV infection Osamu Yoshida Received Received
  THU-469 Active chronic hepatitis B increases the risk of liver metastasis - a retrospective observational study of 7,187 consecutive newly diagnosed colorectal cancer Yue Yang Received Received
  THU-470 Identification and etiology-dependent evaluation of diagnostic algorithms for early detection of hepatocellular carcinoma Dave Morgenstern Received Received
  FRI-470 Diagnostic performance of PIVKA-II in patients with hepatocellular carcinoma Claudio Galli Received Received
  THU-471 Optimisation and qualification of tumour mutational burden (TMB) by targeted next-generation sequencing (TNGS) as a clinically applicable biomarker in hepatocellular carcinoma (HCC) David J. Pinato Received Received
  FRI-471 TGF-beta-associated circular RNAs in cholangiocarcinoma: mechanisms and biomarkers Corentin LOUIS Received Received
  FRI-472 Tracking neutrophils within the hepatocellular carcinoma microenvironment - development of relevant orthotopic and ex-vivo 3D liver-HCC culture models Daniel Geh Received Received
  THU-472 Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma David J. Pinato Received Received
  FRI-473 Identification of PD-L1- expressing exosome-derived microRNAs in human hepatocellular carcinoma Yu Rim Lee Received Received
  THU-476 Circulating microRNA-21 and microRNA-122: prognosis prediction and correlation with HIF-1alpha in hepatocellular carcinoma patients treated with transarterial chemoembolization Filippo Pelizzaro Received Received
  FRI-476 Identification of neoantigens as potential vaccines in hepatocellular carcinoma David Reparaz Received Received
  FRI-478 Development of personalised human immunocompetent ex vivo models of primary and secondary liver cancers using precision cut tissue slice technology Ewald Doornebal Received Received
  SAT-479 Transarterial radioembolization versus systemic treatment for the management of hepatocellular carcinoma with vascular invasion: analysis of the US national cancer database Joseph Ahn Received Received
  THU-479 Prognostic and diagnostic role of angiogenesis biomarkers in hepatocellular carcinoma treated with chemoembolization Giulia Peserico Received Received
  SAT-480 ALBI grade is a good predictive parameter for prognosis in advanced HCC patients with nivolumab therapy Wei Teng Received Received
  THU-481 The combination of EpCAM-positive circulating tumor cells and serum AFP/AFP-L3/DCP predicts outcome after curative resection of hepatocellular carcinoma Johann von Felden Received Received
  SAT-482 The volume of enhancement of disease (VED) predicts the early response to treatment and overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib Claudia Campani Received Received
  THU-482 Intratumoral EpCAM-positive cancer stem cell heterogeneity in patients with hepatocellular carcinoma and its impact on clinical outcome Jenny Krause Received Received
  FRI-482 Comprehensive analysis of cancer-related genes and AAV/hepatitis B virus integration into genome on development of hepatocellular carcinoma in patients with prior hepatitis B virus infection Fukiko Kawai-Kitahata Received Received
  THU-483 Quantitative magnetic resonance imaging predicts individual future liver performance after liver reception for cancer John Connell Received Received
  FRI-484 TIGIT and PD1 dual checkpoint blockade restores functionality of tumor-infiltrating T cells in hepatocellular carcinoma Zhouhong Ge Received Received
  SAT-484 HBsAg relapse after living donor liver transplantation in hepatocelluler carcinoma patients with hepatitis D virus infection may result in hepatocellular carcinoma relapse Adil Baskiran Received Received
  FRI-485 Regulation of the biology of cholangiocarcinoma (CCA) cells by the extracellular-signal regulated kinase 5 (ERK5) Giulia Lori Received Received
  THU-485 Predicting survival after hepatocellular carcinoma resection using deep-learning on histological slides Julien Calderaro Received Received
  FRI-486 Fatty acids regulate the biology of cholangiocarcinoma cells Giulia Lori Received Received
  SAT-486 Influence of acute kidney injury on the prognosis of patients receiving transarterial transembolisation for hepatocellular carcinoma: based on ICA-AKI criteria Won Sohn Received Received
  THU-486 Deep learning for cost-effective accurate diagnosis of liver tumor based-on magnetic resonance imaging and clinical information: a retrospective study Shihui Zhen Received Received
  FRI-488 Modelling liver tumor organoids and cancer-associated fibroblasts interaction reveals the robust effects of stromal niche in cancer nurturing and treatment resistance Jiaye Liu Received Received
  THU-488 The risk of hepatocellular carcinoma recurrence following resection or ablation is dependent on underlying etiology Laura Telep Received Received
  THU-490 The protective role of urea-containing cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma Young-Sun Lee Received Received
  SAT-490 Mutations in circulating tumor DNA predict primary resistance to systemic therapies in patients with advanced hepatocellular carcinoma Johann von Felden Received Received
  FRI-490 ZEB1 promotes cholangiocarcinoma progression through tumor dedifferentiation and paracrine signaling between tumor cells and cancer-associated fibroblasts Javier Vaquero Received Received
  THU-491 Applicability of the six and twelve model in patients with hepatocellular carcinoma treated with DEB-TACE Maria Pipa Muñiz Received Received
  SAT-491 Diagnostic value of brush cytology alone and in combination with tumor marker in malignant biliary stricture Jaseem Ansari Received Received
  FRI-493 Interplay of PNPLA and HSD17B13 variants in modulating the risk of hepatocellular carcinoma among hepatitis C virus infected patients Carla De Benedittis Received Received
  FRI-494 Alisporivir, a cyclophilin inhibitor, reduces fibrosis and tumor burden derived from non-alcoholic steatohepatitis in a mouse model Joseph Kuo Received Received
  SAT-495 Safety and efficacy of lenvatinib in Child-Pugh A and B patients with unresectable hepatocellular carcinoma in clinical practice Katsuaki Ogushi Received Received
  SAT-496 Analyses of intermediate-stage hepatocellular carcinoma patients receiving transarterial chemoembolization before designing clinical trials comparing transarterial chemoembolization and immune checkpoint inhibitor-based therapies Keisuke Koroki Received Received
  FRI-496 SPARC negatively correlates with prognosis after transarterial chemoembolization and facilitates growth and metastasis of hepatocellular carcinoma via ERK/MMP signaling pathways Yao Liu Received Received
  THU-496 Impact of baseline hepatitis B viremia and management on outcomes in advanced hepatocellular carcinoma and elevated alpha-fetoprotein: outcomes from REACH-2 Sukanya Chaudhury Received Received
  FRI-497 Patient-derived ECM-scaffolds of colorectal cancer and liver metastases as organotypic 3D model of liver metastatic colonization Luca Urbani Received Received
  SAT-497 High rate of hepatitis B virus S-integrated human extra spindle pole bodies like 1 fusion gene is detected in hepatitis B virus-related liver cancer patients: a Chinese case-control study Rongming Wang Received Received
  FRI-498 Interplay between O-GlcNAc transferase and enhancer of zeste homolog 2 in hepatocellular carcinoma Margot Thirion Received Received
  SAT-499 Chlorogenic acid decreases malignant characteristics of hepatocellular carcinoma cells by inhibiting DNMT1 expression Yao Liu Received Received
  SAT-500 Protective role of aspirin chronic assumption in patients treated with sorafenib for hepatocellular carcinoma Luca Ielasi Received Received
  FRI-500 Mitochondrial oxidative metabolism contributes to maintain a cancer stem cell phenotype in cholangiocarcinoma chiara raggi Received Received
  THU-501 Refining the immune class of hepatocellular carcinoma Roser Pinyol Received Received
  FRI-502 NEDD8 specific protease 1 (NEDP1) as a tumor suppressor in hepatocellular carcinoma Marina Serrano-Macia Received Received
  THU-503 Cholangiocarcinoma miscoding in hepatobiliary centres Shaun Selvadurai Received Received
  FRI-503 Piddosome-controlled liver ploidy is predictive for HCC outcome Nataliya Rohr-Udilova Received Received
  SAT-503 The six-and-twelve score in a prospective cohort of patients with hepatocellular carcinoma treated with trans-arterial chemoembolization following a fixed schedule Marco Sanduzzi Zamparelli Received Received
  SAT-504 Hepatic arterial infusion chemotherapy combined with sorafenib versus sorafenib monotherapy in advanced hepatocellular carcinoma: a systemic review and meta-analysis Zhiyuan Yao Received Received
  SAT-505 Dexamethasone prophylaxis of postembolization syndrome after transcatheter arterial chemoembolization: a randomized, double-blind, placebo-controlled study Panot Sainamthip Received Received
  THU-505 Transcriptome profiling of liver biopsies before antiviral treatment start can predict HCC development 8.3 years before clinical diagnosis in chronic hepatitis B and C patients Stijn Van Hees Received Received
  THU-506 TERT mutated circulating tumor DNA is a useful biomarker and predicts prognosis in Danish HCC patients Stine Karlsen Oversoe Received Received
  FRI-507 A pro-inflammatory variant in the TLR5 gene is associated with hepatocellular carcinoma in patients with cirrhosis due to steatohepatitis. Philipp Lutz Received Received
  THU-508 Cholangiocarcinoma in England - a national study examining changes in incidence, diagnostic routes and overall survival Shahid Khan Received Received
  FRI-509 Hepatitis B virus surface antigen inactivates the hippo pathway and thereby increases the hepatic expression of oncogene BMI1 Ruth Broering Received Received
  THU-510 Prognostication of hepatocellular carcinoma under sorafenib: external validation of the PROSASH-II model Vito Sansone Received Received
  FRI-510 Natural killer cells target XPO1: a therapeutic opportunity for HCC Salim Khakoo Received Received
  FRI-511 Myeloid IRE1a deletion alters hepatic macrophage phenotype and attenuates experimental non-alcoholic steatohepatitis-related hepatocellular carcinoma Sanne Van Campenhout Received Received
  THU-515 Chronological improvement in long-term outcomes of surgical resection for patients with hepatocellular carcinoma: two large-volume center studies Yun Bin Lee Received Received
  SAT-515 Antiplatelet therapy improves the prognosis of patients with hepatocellular carcinoma TSUGURU HAYASHI Received Received
  FRI-515 BAP1 loss in hepatocellular carcinoma is associated to PKA activation and fibrolamellar features Theo Hirsch Received Received
  SAT-516 No risk of hepatitis B reactivation in hepatocellular carcinoma patients with HBV-DNA 100 iu/ml undergoing immune checkpoint inhibitor immunotherapy by pre-emptive strategy Pei-Chang Lee Received Received
  THU-518 Indeterminate nodules in hepatocellular carcinoma surveillance: an analysis of the frequency, outcomes and costs Yu Meng Li Received Received
  THU-519 Serum creatinine / cystatin C ratio has a potential as a useful surrogate marker for evaluation of muscle mass volume in patients with hepatocellular carcinoma Kazufumi Kobayashi Received Received
  SAT-519 Comparative effectiveness of nivolumab versus regorafenib for hepatocellular carcinoma patients who experienced sorafenib failure Yun Bin Lee Received Received
  SUN-999 My Poster Art Vandelay Received Received
  SAT-999 This is my poster Art Vandeley Received Received
  SUN-1001 Cyriacs Poster Cyriac Couvas Received Received
Manage Orders

Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 27/07/2020 TO 27/08/2021
Oral Presentation
& Video Gallery
Poster Discussion
                   DOI: 10.3252/ 
Submit your poster online
in powerpoint format

   Poster submission deadline 03/08/2020
Upload Poster
Upload Oral Presentation of Video
Upload Oral
Presentation or Video

Logo Draft
Logo Cert